U.S. patent application number 12/646228 was filed with the patent office on 2010-06-24 for target populations of oligodendrocyte precursor cells and methods of making and using same.
Invention is credited to Alexandra Capela, Nobuko Uchida.
Application Number | 20100158878 12/646228 |
Document ID | / |
Family ID | 41630560 |
Filed Date | 2010-06-24 |
United States Patent
Application |
20100158878 |
Kind Code |
A1 |
Capela; Alexandra ; et
al. |
June 24, 2010 |
TARGET POPULATIONS OF OLIGODENDROCYTE PRECURSOR CELLS AND METHODS
OF MAKING AND USING SAME
Abstract
This application provides for enriched target populations
oligodendrocyte precursor cells (OPCs) that can differentiate into
oligodendrocytes. The target OPCs may be expanded and optionally
subjected to conditions to induce their differentiation into
oligodendrocytes. The target OPCs and their progeny are useful for
the treatment of disease associated with demyelination of central
nervous system axons.
Inventors: |
Capela; Alexandra; (Mountain
View, CA) ; Uchida; Nobuko; (Palo Alto, CA) |
Correspondence
Address: |
MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C
ONE FINANCIAL CENTER
BOSTON
MA
02111
US
|
Family ID: |
41630560 |
Appl. No.: |
12/646228 |
Filed: |
December 23, 2009 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61140410 |
Dec 23, 2008 |
|
|
|
Current U.S.
Class: |
424/93.7 ;
435/325; 435/377; 435/7.21 |
Current CPC
Class: |
C12N 2501/115 20130101;
C12N 2501/135 20130101; A61P 25/28 20180101; C12N 5/0622 20130101;
C12N 2501/105 20130101; A61P 37/06 20180101 |
Class at
Publication: |
424/93.7 ;
435/325; 435/7.21; 435/377 |
International
Class: |
A61K 45/00 20060101
A61K045/00; C12N 5/071 20100101 C12N005/071; G01N 33/567 20060101
G01N033/567; A61P 25/28 20060101 A61P025/28; A61P 37/06 20060101
A61P037/06 |
Claims
1. An enriched population of oligodendrocyte precursor cells (OPCs)
derived from neural or neural derived cells, wherein the population
is enriched for target OPCs that are PDGFR.alpha..sup.+ and
CD105.sup.-, wherein at least 30% of the cells in the population
are target OPCs.
2. The population of claim 1, where in the target cells are also
PSA-NCAM.sup.lo/-.
3. The population of claim 1, where in the target cells are also
A2B5.sup.lo/-.
4. The population of claim 1, where in the target cells are also
CD133.sup.+.
5. The population of OPCs in claim 1, wherein at least 50% of the
cells in the population are target OPCs.
6. The population of OPCs in claim 1, wherein at least 70% of the
cells in the population are target OPCs.
7. The population of OPCs in claim 1, wherein at least 90% of the
cells in the population are target OPCs.
8. The population of OPCs in claim 1, wherein the target OPCs are
PDGFR.alpha..sup.+, CD105.sup.-, CD133.sup.+, and A2B5.sup.-.
9. The population of OPCs in claim 1, wherein the target OPCs are
PDGFR.alpha..sup.+, CD105.sup.-, CD133.sup.+, A2B5.sup.lo/-, and
PSA-NCAM.sup.-.
10. A method of producing population of cells enriched for target
oligodendrocyte precursor cells (OPCs) from neural or neural
derived cells, comprising contacting neural or neural derived cells
with at least one reagent that binds to cell surface antigens
expressed by the target OPCs, wherein the target OPCs are
PDGFR.alpha..sup.+ and CD105.sup.-, wherein the population of cells
is enriched to contain at least 30% target OPC.
11. The method of claim 10, wherein the target OPCs are also
PSA-NCAM.sup.lo/-.
12. The method of claim 10, where in the target cells are also
A2B5.sup.lo/-.
13. The method of claim 10, where in the target cells are also
CD133.sup.+.
14. The method of claim 10 further comprising negatively selecting
for target OPCs by selectively removing nontarget cell
populations.
15. The method of claim 10, wherein the target OPCs are
PDGFR.alpha..sup.+, CD105.sup.-, CD133.sup.+, and A2B5.sup.-.
16. The method of claim 10, wherein the target OPCs are
PDGFR.alpha..sup.+, CD105.sup.-, CD133.sup.+, A2B5.sup.lo/-, and
PSA-NCAM.sup.-.
17. A method of increasing the number of target oligodendrocyte
precursor cells (OPCs) in a cell culture comprising culturing a
population of cells comprising at least 30% target OPCs to increase
the number of target OPCs in the cell culture, wherein the target
OPCs are PDGFR.alpha..sup.+ and CD105.sup.-.
18. The method of claim 17, wherein the target OPCs are also
PSA-NCAM.sup.lo/-.
19. The method of claim 17, where in the target cells are also
A2B5.sup.lo/-.
20. The method of claim 17, where in the target cells are also
CD133.sup.+.
21. The method of claim 17, wherein the target OPCs are
PDGFR.alpha..sup.+, CD105.sup.-, CD133.sup.+, and A2B5.sup.-.
22. The method of claim 17, wherein the target OPCs are
PDGFR.alpha..sup.+, CD105.sup.-, CD133.sup.+, A2B5.sup.lo/-, and
PSA-NCAM.sup.-.
23. The method of claim 17 further comprising contacting the OPCs
with an effective amount of at least one biological agent that is
capable of increasing the number of OPCs.
24. The method of claim 23 wherein the biological agent is selected
from the group consisting of leukemia inhibitory factor (LIF),
epidermal growth factor (EGF), basic fibroblast growth factor
(FGF-2; bFGF), IGF-1, NT3, Shh, CTNF, PDGF-AA and combinations
thereof.
25. A method for proliferating oligodendrocyte precursor cells
(OPCs) comprising: proliferating OPCs in serum-free culture medium
containing one or more predetermined growth factors effective for
inducing OPC proliferation, wherein: (a) the population comprises
OPCs which are PDGFR.alpha..sup.+ and CD105.sup.-; and (b) in the
presence of differentiation-inducing conditions, the cells produce
progeny cells that differentiate into oligodendrocytes.
26. The method of claim 25, wherein the OPCs are also
PSA-NCAM.sup.lo/-.
27. The method of claim 25, where in the target cells are also
A2B5.sup.lo/-.
28. The method of claim 25, where in the target cells are also
CD133.sup.+.
29. The method of claim 25 further comprising subjecting the OPCs
to culture conditions that induce oligodendrocyte differentiation
to produce differentiating and differentiated oligodendrocytes.
30. A composition comprising the oligodendrocyte precursor cells
(OPCs) produced by the method of claim 25.
31. A composition comprising the differentiating or differentiated
oligodendrocytes produced by the method of claim 25.
32. A method of treating a mammalian individual suffering from a
disease associated with demyelination of central nervous system
axons, comprising introducing the enriched population of OPCs of
claim 1 to the mammalian individual in an amount effective to treat
the disease.
33. The method of claim 32, wherein the mammalian individual is a
human.
34. The method of claim 32, wherein the OPCs are administered to
the mammalian individual by cell transplantation.
35. The method of claim 32, wherein the disease is multiple
sclerosis, Pelizaeus-Merzbacher disease, cerebral palsy, radiation
induced myelination disorders, acute disseminated
encephalomyelitis, transverse myelitis, demyelinating genetic
disease, spinal cord injury, virus-induced demyelination,
Progressive Multifocal Leucoencephalopathy, Human Lymphotrophic
T-cell Virus I (HTLVI)-associated myelopathy, or nutritional
metabolic disorder.
36. The method of claim 32, wherein the disease is multiple
sclerosis, Pelizaeus-Merzbacher disease, or cerebral palsy.
37. A method of treating a mammalian individual suffering from a
disease associated with demyelination of central nervous system
axons, comprising introducing the OPCs of claim 1 to the mammalian
individual in an amount effective to treat the disease.
38. The method of claim 37, wherein the mammalian individual is a
human.
39. The method of claim 37, wherein the OPCs are administered to
the mammalian individual by cell transplantation.
40. The method of claim 37, wherein the disease is multiple
sclerosis, acute disseminated encephalomyelitis, transverse
myelitis, demyelinating genetic disease, spinal cord injury,
virus-induced demyelination, Progressive Multifocal
Leucoencephalopathy, Human Lymphotrophic T-cell Virus I
(HTLVI)-associated myelopathy, or nutritional metabolic
disorder.
41. A method of treating a mammalian individual suffering from a
disease associated with demyelination of central nervous system
axons, comprising introducing the differentiating or differentiated
oligodendrocytes prepared according to the method of claim 21 to
the mammalian individual in an amount effective to treat the
disease.
42. The method of claim 41, wherein the mammalian individual is a
human.
43. The method of claim 41, wherein the differentiating or
differentiated oligodendrocytes are administered to the mammalian
individual by cell transplantation.
44. The method of claim 41, wherein the disease is multiple
sclerosis, acute disseminated encephalomyelitis, transverse
myelitis, demyelinating genetic disease, spinal cord injury,
virus-induced demyelination, Progressive Multifocal
Leucoencephalopathy, Human Lymphotrophic T-cell Virus I
(HTLVI)-associated myelopathy, or nutritional metabolic
disorder.
45. A method of screening for compounds that affect a biological
function of an enriched population of target oligodendrocyte
precursor cells comprising: (a) contacting an enriched population
of target oligodendrocyte precursor cells obtained by the method of
claim 1 with a test compound; and (b) detecting a change in a
biological function of the oligodendrocyte precursor cells.
46. The method of claim 45, wherein said target oligodendrocyte
precursor cells are PDGFR.alpha..sup.+, CD105.sup.-, A2B5.sup.lo/-,
PSA-NCAM.sup.lo/-, and CD133.sup.+.
47. The method of claim 45, wherein said target oligodendrocyte
precursor cells are PDGFR.alpha..sup.+, CD105.sup.-, A2B5.sup.-,
and CD133.sup.+.
48. The method of claim 45, wherein said target oligodendrocyte
precursor cells are PDGFR.alpha..sup.+, CD105.sup.-, A2B5.sup.lo/-,
PSA-NCAM.sup.-, and CD133.sup.+.
49. The method of claim 45, wherein the change occurs in at least
one of the characteristics selected from the group consisting of
myelination, differentiation into oligodendrocytes, proliferation
rate, cell migration, viability, gene expression, protein
expression, protein levels in the culturing medium,
dedifferentiation, growth characteristics, and cell morphology.
50. A method of producing a population enriched for oligodendrocyte
precursor cells comprising: (a) contacting neural or neural derived
cells comprising one or more multipotent central nervous system
stem cell with an antibody that specifically binds to PDGFR.alpha.;
and (b) selecting said neural or neural derived cells that are
PDGFR.alpha..sup.hi, wherein the selected cells are enriched for
oligodendrocyte precursor cells as compared with the neural or
neural derived cells.
51. The method of claim 50, wherein said neural or neural derived
cells are obtained from a neuro sphere culture or an adherent
culture.
52. The method of claim 50, wherein the method further comprises
the step of eliminating those cells that are
PDGFR.alpha..sup.lo/med.
53. The method of claim 50, wherein the method further comprises
the step of eliminating cells that are CD105.sup.-.
Description
RELATED APPLICATIONS
[0001] This application claims the benefit of priority to U.S.
Provisional Application No. 61/140,410, filed Dec. 23, 2008.
FIELD OF THE INVENTION
[0002] This invention relates to isolation, characterization,
proliferation, differentiation and transplantation of a population
of oligodendrocyte precursor cells.
BACKGROUND
[0003] During development of the central nervous system ("CNS"),
multipotent neural precursor cells, also known as neural stem
cells, proliferate and give rise to transiently dividing progenitor
cells that eventually differentiate into the cell types that
compose the adult brain. Stem cells (from other tissues) have
classically been defined as having the ability to self-renew (i.e.,
form more stem cells), to proliferate, and to differentiate into
different phenotypic lineages. In the case of neural stem cells,
this includes neurons, astrocytes and oligodendrocytes. Neural stem
cells have been isolated from several mammalian species, including
mice, rats, pigs and humans. See, e.g., WO 93/01275, WO 94/09119,
WO 94/10292, WO 94/16718 and Cattaneo et al., Mol. Brain. Res., 42,
pp. 161-66 (1996), the disclosures of which are herein incorporated
by reference in their entireties. The main function of
oligodendrocytes is the myelination of axons in the central nervous
system of higher vertebrates. Oligodendrocyte precursor cells
(OPCs) precede oligodendrocytes.
SUMMARY
[0004] The invention provides for enriched target populations of
oligodendrocyte precursor cells (OPCs) that can further
differentiate into oligodendrocytes. According to some embodiments,
populations of OPCs are provided that are substantially enriched
for cells expressing the PDGFR.alpha. antigen.
[0005] According to some embodiments, the target OPCs are
PDGFR.alpha..sup.+ and additionally CD105.sup.-. According to some
embodiments, the target populations of cells are enriched for OPCs
that are immunopositive for PDGFR.alpha. (PDGFR.alpha..sup.+) and
immunonegative for CD105 (CD105.sup.-). According to some
embodiments, the target populations of cells are enriched for OPCs
that are immunopositive for PDGFR.alpha. (PDGFR.alpha..sup.+),
immunopositive for CD133 (CD133.sup.+), and immunonegative for
CD105 (CD105.sup.-).
[0006] According to some embodiments, the target OPCs are
PDGFR.alpha..sup.+ and additionally A2B5.sup.lo, A2B5.sup.-, or
mixture thereof (A2B5.sup.lo/-). According to some embodiments, the
target populations of cells are enriched for OPCs that are
immunopositive for PDGFR.alpha. (PDGFR.alpha..sup.+),
immunopositive for CD133 (CD133.sup.+), and immunonegative for A2B5
(A2B5.sup.-). According to some embodiments, the target population
of OPCs are PDGFR.alpha..sup.+, A2B5.sup.lo/-. According to some
other embodiments, the target population of OPCs are
PDGFR.alpha..sup.+, CD133.sup.+, A2B5.sup.-. According to some
other embodiments, the target population of OPCs are
PDGFR.alpha..sup.+, CD133.sup.+, A2B5.sup.lo/-. According to some
other embodiments, the target population of OPCs are
PDGFR.alpha..sup.+, CD133.sup.+, A2B5.sup.-, PSA-NCAM.sup.-.
According to some other embodiments, the target population of OPCs
are PDGFR.alpha..sup.+, CD133.sup.+, A2B5.sup.lo/-, PSA-NCAM.sup.-.
According to some other embodiments, the target population of OPCs
are PDGFR.alpha..sup.+, CD133.sup.+, A2B5.sup.-, PSA-NCAM.sup.lo/-.
According to some other embodiments, the target population of OPCs
are PDGFR.alpha..sup.+, CD133.sup.+, A2B5.sup.lo/-,
PSA-NCAM.sup.lo/-.
[0007] According to some embodiments, the target OPCs are
PDGFR.alpha..sup.+, CD105.sup.- and additionally A2B5.sup.lo,
A2B5.sup.-, or mixture thereof (A2B5.sup.lo/-). According to some
embodiments, the target populations of cells are enriched for OPCs
that are immunopositive for PDGFR.alpha. (PDGFR.alpha..sup.+),
immunopositive for CD133 (CD133.sup.+), immunonegative for A2B5
(A2B5.sup.-), and immunonegative for CD105 (CD105.sup.-). According
to some embodiments, the target population of OPCs are
PDGFR.alpha..sup.+, CD105.sup.-, A2B5.sup.lo/-. According to some
other embodiments, the target population of OPCs are
PDGFR.alpha..sup.+, CD133.sup.+, CD105.sup.-, A2B5.sup.-. According
to some other embodiments, the target population of OPCs are
PDGFR.alpha..sup.+, CD133.sup.+, CD105.sup.-, A2B5.sup.lo/-.
According to some other embodiments, the target population of OPCs
are PDGFR.alpha..sup.+, CD133.sup.+, CD105.sup.-, A2B5.sup.-,
PSA-NCAM.sup.-. According to some other embodiments, the target
population of OPCs are PDGFR.alpha..sup.+, CD133.sup.+,
CD105.sup.-, A2B5.sup.lo/-, PSA-NCAM.sup.-. According to some other
embodiments, the target population of OPCs are PDGFR.alpha..sup.+,
CD133.sup.+, CD105.sup.-, A2B5.sup.-, PSA-NCAM.sup.lo/-. According
to some other embodiments, the target population of OPCs are
PDGFR.alpha..sup.+, CD133.sup.+, CD105.sup.-, A2B5.sup.lo/-,
PSA-NCAM.sup.lo/-.
[0008] According to some embodiments, methods of identifying,
isolating, or enriching target populations of oligodendrocyte
precursor cells, are achieved by contacting a population of cells
containing at least one OPC with a reagent that binds to the
surface marker antigen expressed on the cell surface of an OPC.
According to preferred embodiments, enriched populations of target
oligodendrocyte precursor cells are achieved by contacting a
population of cells containing at least one OPC with a reagent that
binds to PDGFR.alpha.. Preferably, the reagent is an antibody that
binds to PDGFR.alpha.. Use of traditional techniques for cell
sorting, such as by immunoselection (e.g., FACS), permits
identification, isolation, and/or enrichment for cells in which
contact between the reagent and the PDGFR.alpha. antigen has been
detected.
[0009] According to some embodiments, the invention provides
methods for producing populations enriched for target
oligodendrocyte precursor cells by contacting neural or neural
derived cells with a monoclonal antibody that binds to a negative
selection marker that is not found on the target oligodendrocyte
precursor cells; selecting the cells that bind to this monoclonal
antibody; and removing the bound cells. The remaining cells in the
population are enriched for oligodendrocyte precursor cells. Those
skilled in the art will recognize that a negative selection marker
is a marker (i.e., an antigen) that is present only on non-OPC
cells. In various embodiments, the monoclonal antibody may be
fluorochrome conjugated or may be conjugated to magnetic particles,
and the selection may be by fluorescence activated cell sorting,
high gradient magnetic selection, by attachment to and
disattachment from the solid phase, or any other commonly used
selection technique. In preferred embodiments, the population
containing neural or neural-derived cells is obtained from a
suspension culture, an adherent culture, or from fresh neural
tissue. These methods may also involve the step of further
enriching the population for oligodendrocyte precursor cells by
contacting the remaining cells with a second antibody or series of
antibodies. For example, target populations of OPCs may be enriched
by contacting the culture of neural or neural derived cells with an
antibody that specifically binds to CD133 followed by contacting
the remaining cells with an antibody that specifically binds
PDGFR.alpha. to produce populations enriched for oligodendrocyte
precursor cells that are immunopositive for both CD133 and
PDGFR.alpha.. In addition the culture of neural or neural derived
cells may be contacted with an antibody that specifically binds
PDGFR.alpha. to produce populations enriched for OPCs that are
immunopositive for PDGFR.alpha..
[0010] According to some embodiments, the invention provides
methods for isolating a oligodendrocyte precursor cell (OPC), by
selecting from a population of neural or neural-derived cells for
cells that are immunopositive for CD133 (CD133.sup.+ cells);
eliminating the non-immunoreactive (CD133.sup.-) cells from the
population; and selecting from the remaining population for at
least one cell that is immunopositive for PDGFR.alpha.
(PDGFR.alpha..sup.+), e.g., binds to monoclonal antibody
PDGFR.alpha.. In other embodiments, the invention provides methods
for producing a population enriched for oligodendrocyte precursor
cells by contacting neural or neural derived cells containing at
least one multipotent neural stem cell with an antibody that
specifically binds to PDGFR.alpha. and selecting those cells that
are PDGFR.alpha..sup.hi, wherein the selected cells are enriched
for oligodendrocyte precursor cells as compared with the neural or
neural derived cells. Those skilled in the art will recognize that
the neural or neural derived cells can be obtained from a
neurosphere culture (cell clusters or cell aggregates) or from an
adherent culture. In some embodiments, this method also involves
the step of eliminating those cells that are
PDGFR.alpha..sup.lo/med from the population.
[0011] According to some embodiments, the invention provides
methods for isolating a oligodendrocyte precursor cell (OPC), by
selecting from a population of neural or neural-derived cells for
cells that are immunonegative for CD105 (CD105.sup.- cells);
eliminating the immunoreactive (CD105.sup.+) cells from the
population; and selecting from the remaining population for at
least one cell that is immunopositive for PDGFR.alpha.
(PDGFR.alpha..sup.+), e.g., binds to monoclonal antibody
PDGFR.alpha.. According to some embodiments, the invention provides
methods for isolating a oligodendrocyte precursor cell (OPC), by
selecting from a population of neural or neural-derived cells for
cells that are immunopositive for PDGFR.alpha.
(PDGFR.alpha..sup.+), e.g., binds to monoclonal antibody
PDGFR.alpha.; eliminating the non-immunoreactive
(PDGFR.alpha..sup.-) cells from the population; and selecting from
the remaining population for at least one cell that is
immunonegative for CD105 (CD105.sup.-).
[0012] In other embodiments, the invention provides methods for
producing a population enriched for oligodendrocyte precursor cells
by contacting neural or neural derived cells containing at least
one multipotent neural stem cell with an antibody that specifically
binds to PDGFR.alpha. and selecting those cells that are
PDGFR.alpha..sup.hi, wherein the selected cells are enriched for
oligodendrocyte precursor cells as compared with the neural or
neural derived cells. Those skilled in the art will recognize that
the neural or neural derived cells can be obtained from a
neurosphere culture or from an adherent culture. In some
embodiments, this method also involves the step of eliminating
those cells that are PDGFR.alpha..sup.lo/med from the
population.
[0013] According to some embodiments, the invention provides
methods for producing a population enriched for oligodendrocyte
precursor cells by eliminating cells that are positive for markers
of differentiated cells or fibroblasts cells from a population of
neural or neural-derived cells (e.g., CD105). This may be
accomplished by contacting the population with a monoclonal
antibody directed to such markers of differentiated cells and
removing those cells that bind to this monoclonal antibody. This
resulting population of cells may be further enriched using any of
the methods described herein. By way of non-limiting example, the
method may involve the step of further enriching the population for
oligodendrocyte precursor cells by contacting the remaining cells
with an antibody that specifically binds to PDGFR.alpha.. In
various other preferred embodiments, the fraction may optionally be
enriched by selecting from the remaining cells for cells are
PDGFR.alpha..sup.+, CD105.sup.-, CD133.sup.+, A2B5.sup.lo/-,
PSA-NCAM.sup.lo/- and mixtures and combinations thereof.
[0014] According to additional embodiments, the invention provides
methods for proliferating enriched populations of oligodendrocyte
precursor cells by introducing at least one selected cell to a
serum-free culture medium containing one or more growth factors
selected from the group consisting of LIF, EGF, bFGF, PDGF-AA,
PDGF-AB, PDGF-BB, Sonic hedgehog (Shh), IGF1, CTNF, Noggin, and NT3
and combinations thereof; and proliferating at least one selected
cell in the culture medium. Preferably, the method for
proliferating enriched populations of oligodendrocyte precursor
cells comprises introducing at least one selected cell to a
serum-free culture medium containing one or more growth factors
selected from the group consisting of PDGF-AA, NT3, bFGF, IGF1 and
combinations thereof; and proliferating at least one selected cell
in the culture medium.
[0015] Also provided are methods of proliferating and
differentiating target OPCs. According to some embodiments, the
induction of proliferation (and differentiation) of the OPCs can be
done either by culturing the cells in suspension or on a substrate
onto which they can adhere. Alternatively, proliferation and
differentiation of OPCs can be induced, under appropriate
conditions, in the host in the following combinations: (1)
proliferation and differentiation in vitro, then transplantation,
(2) proliferation in vitro, transplantation, then further
proliferation and differentiation in vivo, (3) proliferation in
vitro, transplantation and differentiation in vivo, and (4)
proliferation and differentiation in vivo. Proliferation and
differentiation in vivo or in situ can involve a non-surgical
approach that coaxes OPCs to proliferate in vivo with
pharmaceutical manipulation.
[0016] According to some embodiments, methods are provided for
treating or ameliorating a demyelinating or dysmyelinating disease
or disorder in a mammal, comprising administering to the mammal a
target OPC or a population of target OPCs.
[0017] The mammal preferably harbors a demyelinating or
dysmyelinating disease, including, but not limited to, multiple
sclerosis, acute disseminated encephalomyelitis, diffuse cerebral
sclerosis, necrotizing hemorrhagic encephalitis, radiation induced
myelination disorders, transverse myelitits, Pelizaeus-Merzbacher
disease (PMD), Cerebral palsy (CP), and leukodystrophies. The
disease is preferably multiple sclerosis, Pelizaeus-Merzbacher
disease, or Cerebral palsy. The mammal may additionally receive at
least one biological agent that is capable of increasing the number
of OPCs and/or at least one factor that is known to stimulate
oligodendrocyte differentiation, growth, proliferation, or
survival. The OPCs, oligodendrocyte promoting factor(s), biological
agent(s), and/or other factor(s) may be administered in any manner
that results in contact of the factor and or agent with target OPCs
in the mammal, such as systemically (e.g., subcutaneously) or in
situ. Preferably, the OPCs, oligodendrocyte promoting factor(s),
biological agent(s), and/or other factor(s) may be administered
into the brain, more preferably into the lateral ventricle of the
brain or into the brain parenchyma.
BRIEF DESCRIPTION OF THE DRAWINGS
[0018] FIG. 1. Sagital section of shiverer/scid mouse counter
stained with methyl green to highlight cell nuclei. Arrows indicate
the 3 areas of the brain injected with human OPCs. Abbreviations:
cc, corpus callosum; fb, fimbria; cb, cerebellum.
[0019] FIG. 2. Example of OPC engraftment in the neonatal
shiverer/scid mouse. Top panel shows sc121 staining, highlighting
all donor derived cells. The bottom panel shows MBP staining in a
serial sister section. Dotted regions of interest have been drawn
to indicate the areas of engraftment and of corresponding
myelination. In this example, the superior colliculus was targeted.
Cell line information: FBr 2711, P6, 8 weeks post transplant.
Abbreviations used: str, striatum; cc, corpus callosum; sc,
superior colliculus.
[0020] FIG. 3. Example of MBP-GFP transduced OPC engraftment in the
neonatal shiverer/scid mouse. Top panel shows GFP staining,
highlighting donor derived cells that are actively transcribing the
mbp gene. The bottom panel shows MBP staining in a serial sister
section. Dotted regions of interest have been drawn around the
cerebellum and are shown in the panels on the right at higher
magnification. Note that there is a digital misalignment of the
cerebellum in the MBP panel as indicated by the white arrows. Cell
line information: FBr 2703, P6, 8 weeks post transplant.
Abbreviations used: cb, cerebellum.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0021] Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art to which this invention belongs. Although
methods and materials similar or equivalent to those described
herein can be used in the practice or testing of the present
invention, suitable methods and materials are described below. All
publications, patent applications, patents, and other references
mentioned herein are incorporated by reference in their entirety.
In the case of conflict, the present specification, including
definitions, will control. In addition, the materials, methods, and
examples are illustrative only not intended to be limiting. Other
features and advantages of the invention will be apparent from the
following detailed description and claims.
[0022] The section headings are used herein for organizational
purposes only, and are not to be construed as in any way limiting
the subject matter described.
DEFINITIONS
[0023] For the purposes of promoting an understanding of the
embodiments described herein, reference will be made to preferred
embodiments and specific language will be used to describe the
same. The terminology used herein is for the purpose of describing
particular embodiments only, and is not intended to limit the scope
of the present invention. As used throughout this disclosure, the
singular forms "a," "an," and "the" include plural reference unless
the context clearly dictates otherwise. Thus, for example, a
reference to "a cell" includes a plurality of such cells, and a
reference to "an antibody" is a reference to one or more
antibodies, and so forth.
[0024] As used herein, the term "target cell population" denotes
those cells which are desirably being purified or enriched.
Preferably, the target cell population are oligodendrocyte
precursor cells that display the distinctive pattern of cell
markers as described herein.
[0025] "Oligodendrocytes" (OLs) or oligodendroglia are best known
as the myelin-forming cells of the central nervous system (CNS).
The term "oligodendrocyte precursor cell" or "OPC" refers to the
immature form of oligodendrocytes that are capable of
differentiating into myelin forming cells of the CNS under certain
conditions. This term includes oligodendrocyte precursor cells
isolated from primary tissue and cells cultured in vitro into OPCs,
as well as the progeny of such oligodendrocyte precursor cells, and
thus includes both OPCs and daughter OPCs.
[0026] The term "neural stem cells" is the more general term used
for undifferentiated, multipotent, self-renewing, neural cells. A
neural stem cell is a clonogenic multipotent stem cell which is
able to divide and, under appropriate conditions, has self-renewal
capability and can include in its progeny daughter cells which can
terminally differentiate into neurons, astrocytes, and
oligodendrocytes. Hence, the neural stem cell is "multipotent"
because stem cell progeny have multiple differentiation pathways. A
neural stem cell is capable of self maintenance, meaning that with
each cell division, one daughter cell will also be a stem cell.
[0027] The non-stem cell progeny of a neural stem cell are
typically referred to as "progenitor" or "precursor" cells, which
are capable of giving rise to various cell types within one or more
lineages. The term "neural progenitor cell" or "neural precursor
cell" refers to an undifferentiated cell derived from a neural stem
cell and is not itself a stem cell. Some progenitor cells can
produce progeny that are capable of differentiating into more than
one cell type. For example, an O-2A cell is a glial progenitor cell
that gives rise to oligodendrocytes and type II astrocytes, and,
thus, could be termed a "bipotential" progenitor cell. A
distinguishing feature of a progenitor cell is that, unlike a stem
cell, it does not exhibit self maintenance. Moreover, progenitor
cells are typically thought to be committed to a particular path of
differentiation and will, under appropriate conditions, eventually
differentiate into glia or neurons.
[0028] The terms "neural cells" or "neural derived cells" refers
broadly to cells associated with the central nervous system (CNS)
of an organism, for example, neurons, glial cells, and precursor
cells. As used herein, neural cells may be cells that are isolated
or derived from neural tissue, as well as any cell, regardless of
origin, having at least an indication of neuronal or glial
phenotype, such as staining for one or more neuronal or glial
markers or which will differentiate into cells exhibiting neuronal
or glial markers. Thus, the term may be used as a general term to
refer to, for example, primary cells isolated and cultured in
vitro; cultured immortalized cells derived from a neural tissue,
neural tissue cells; and/or cells cultured to express a neural
phenotype. The term is meant to be all-encompassing with respect to
cells exhibiting a neural cell phenotype and/or isolated from
neural tissue. Thus, the term neural cells also includes cells
which are neural precursor cells as well as differentiated neural
cells. As used herein, the term "neuronal cells" refers to
neurons.
[0029] The term "positive selection" refers to a process in which
the target cell population is purified or enriched by removing the
target cell population from a mixture of cell populations by
directly binding the target cell population to reagents having
affinity therefore.
[0030] In contrast, the term "negative selection" refers to a
process in which the target cell population is purified or enriched
by removing nontarget cell populations from the mixture of cells by
binding the nontarget cell populations to reagents having affinity
therefore. For example, CD45 is the T200/leucocyte common antigen.
Human central nervous system stem cells (CNS-SC), and preferably
those that can initiate neurospheres, and cultures containing them,
are additionally characterized as lacking certain cell surface
markers such as CD45. Thus, reagents that recognize CD45 may be
useful in a negative selection process to remove nontarget
cells.
[0031] A "primary neurosphere" is a neurosphere generated by
culturing brain tissue. Typically, the brain tissue is dissected
and mechanically dissociated before being cultured in appropriate
media and allowed to form neurospheres. Exemplary methods are
described in, for instance, U.S. Pat. No. 5,750,376, the disclosure
of which is incorporated herein by reference in its entirety.
[0032] A "secondary neurosphere" is a neurosphere generated by
dissociating (passaging) a primary neurosphere and culturing the
dissociated cells under conditions which result in the formation of
neurospheres from single cells.
[0033] A "mammal" is any member in the mammalian family. A mammal
is preferably a primate, rodent, feline, canine, domestic livestock
(such as cattle, sheep, goats, horses, and pigs), and most
preferably a human.
[0034] A "demyelinating disease" or a "dysmyelinating disorder" is
a disease, disorder, or medical condition that is caused by or
associated with inadequate amounts myelin. Demyelination is the
process of myelin removal i.e., loss of myelin that existed before.
Dysmyelination occurs where no or inadequate amounts of myelin
forms, e.g., due to dysfunctional OPCs or oligodendrocytes (OLs).
The end result of demyelination and dysmyelination is
hypomyelination. Examples of these diseases, disorders, or
conditions include, for example, multiple sclerosis (including the
relapsing and chronic progressive forms of multiple sclerosis,
acute multiple sclerosis, neuromyelitis optica (Devic's disease)),
diffuse cerebral sclerosis (including Shilder's encephalitis
periaxialis diffusa and Balo's concentric sclerosis). Demyelinating
diseases or dysmyelinating disorders also include a variety of
diseases wherein demyelination is caused by viral infections,
vaccines, spinal cord injury, and genetic disorders. Examples of
these demyelinating diseases or dysmyelinating disorders include
acute disseminated encephalomyelitis (occurring after measles,
chicken pox, rubella, influenza or mumps; or after rabies or small
pox vaccination), necrotizing hemorrhagic encephalitis (including
hemorrhagic leukoencephalitis), and leukodystrophies (including
Krabbe's globboid leukodystrophy, metachromatic leukodystrophy,
adrenoleukodystrophy, adrenomyeloneuropathy, adrenomyeloneuropathy,
radiation induced myelination disorders, transverse myelitits,
Pelizaeus-Merzbacher disease (PMD), Canavan's disease and
Alexander's disease). The demyelinating disease or dysmyelinating
disorder is preferably multiple sclerosis, cerebral palsy, diffuse
cerebral sclerosis, or Pelizaeus-Merzbacher disease (PMD), and,
most preferably, Pelizaeus-Merzbacher disease.
[0035] "Treating" or "ameliorating" means the reduction or complete
removal of the symptoms of a disease or medical condition.
[0036] An "effective amount" is an amount of a therapeutic agent
sufficient to achieve the intended purpose. The effective amount of
a given therapeutic agent will vary with factors such as the nature
of the agent, the route of administration, the size and species of
the animal to receive the therapeutic agent, and the purpose of the
administration. The effective amount in each individual case may be
determined empirically by a skilled artisan according to
established methods in the art.
[0037] The term "ventricle" refers to any cavity or passageway
within the CNS through which cerebral spinal fluid flows. Thus, the
term not only encompasses the lateral, third, and fourth
ventricles, but also encompasses the central canal, cerebral
aqueduct, and other CNS cavities.
[0038] Cell Markers
[0039] This invention provides for the identification, isolation,
enrichment, and culture of oligodendrocyte precursor cells. The
target cell population of OPCs can be characterized by their
expression of cell surface markers. While it is commonplace in the
art to refer to cells as "positive" or "negative" for a particular
marker, actual expression levels are a quantitative trait. The
number of molecules on the cell surface can vary by several logs,
yet still be characterized as "positive". It is also understood by
those of skill in the art that a cell which is negative for
staining, i.e., the level of binding of a marker specific reagent
is not detectably different from a control, e.g. an isotype matched
control; may express minor amounts of the marker. Characterization
of the level of staining permits subtle distinctions between cell
populations.
[0040] The staining intensity of cells can be monitored by flow
cytometry, where lasers detect the quantitative levels of
fluorochrome (which is proportional to the amount of cell surface
marker bound by specific reagents, e.g. antibodies). Flow
cytometry, or FACS, can also be used to separate cell populations
based on the intensity of binding to a specific reagent, as well as
other parameters such as cell size and light scatter. Although the
absolute level of staining may differ with a particular
fluorochrome and reagent preparation, the data can be normalized to
a control.
[0041] In order to normalize the distribution to a control, each
cell is recorded as a data point having a particular intensity of
staining. These data points may be displayed according to a log
scale, where the unit of measure is arbitrary staining intensity.
In one example, the brightest cells in a population are designated
as 4 logs (i.e., 10,000 times) more intense than the cells having
the lowest level of staining. When displayed in this manner, it is
clear that the cells falling in the highest log of staining
intensity are bright, while those in the lowest intensity are
negative. The "low" staining cells, which fall in the 2-3 log(i.e.,
100-1000 fold) of staining intensity, may have properties that are
unique from the negative and positive cells. An alternative control
may utilize a substrate having a defined density of marker on its
surface, for example a fabricated bead or cell line, which provides
the positive control for intensity. The "low" designation indicates
that the level of staining is above the brightness of an isotype
matched control, but is not as intense as the most brightly
staining cells normally found in the population.
[0042] For the purpose of defining staining intensity of a
particular antibody, an isotype matched control will define the
signal intensity of "non-specific" or "negative" staining. Whereas
any staining which results in signal intensity above that of the
control is considered to be "positive" staining. The boundary
demarcating negative and positive staining is conventionally set
such that the frequency of events to the left of, or below, the
boundary is >0.99 and <1.0. Positive staining intensity can
then be further subdivided and categorized as low, medium, or high
by defining an arbitrary scale from the control boundary to the
highest recorded signal intensity and defining two additional lines
of demarcation at the 33.sup.rd and 66.sup.th percentiles,
respectively. Signals measured in the lower-third, middle-third,
and upper-third of these defined groups can then be designated as
low, medium, and high staining intensity, respectively.
[0043] Cell Sorting
[0044] The use of cell surface antigens to isolate, select, or
enrich for OPC cells provides a means for the positive and negative
immunoselection of target OPC populations, as well as for the
phenotypic analysis of target OPC cell populations using flow
cytometry. For the preparation of substantially pure target OPC
populations, a subset of OPCs is separated from other cells on the
basis of PDGFR.alpha. binding. OPCs may be further separated by
binding to other surface markers known in the art. Cells selected
for expression of PDGFR.alpha. antigen, for example, may be further
purified by the positive and negative immunoselection of other
target OPC markers as disclosed herein.
[0045] Procedures for separation may include magnetic separation,
using antibody-coated magnetic beads, affinity chromatography and
"panning" with antibody attached to a solid matrix, e.g. plate, or
other convenient technique. Techniques providing accurate
separation include fluorescence activated cell sorters, which can
have varying degrees of sophistication, such as multiple color
channels, low angle and obtuse light scattering detecting channels,
impedance channels, etc. Dead cells may be eliminated by selection
with dyes associated with dead cells (propidium iodide [PI], LDS).
Any technique may be employed which is not unduly detrimental to
the viability of the selected cells.
[0046] Conveniently, the antibodies are conjugated with labels to
allow for ease of separation of the particular cell type, e.g.
magnetic beads; biotin, which binds with high affinity to avidin or
streptavidin; fluorochromes, which can be used with a fluorescence
activated cell sorter; haptens; and the like. Multi-color analyses
may be employed with the FACS or in a combination of immunomagnetic
separation and flow cytometry. Multi-color analysis is of interest
for the separation of cells based on multiple surface antigens,
e.g. PDGFR.alpha..sup.+, CD105.sup.-, CD133.sup.+, CD24.sup.-, etc.
Fluorochromes which find use in a multi-color analysis include, for
example, phycobiliproteins, e.g. phycoerythrin and
allophycocyanins; fluorescein and Texas red. A negative designation
indicates that the level of staining is at or below the brightness
of an isotype matched negative control. A "dim", "lo", or "low"
designation indicates that the level of staining may be near the
level of a negative stain, but may also be brighter than an isotype
matched control.
[0047] For example, the PDGFR.alpha. antibody is directly or
indirectly conjugated to a magnetic reagent, such as a
superparamagnetic microparticle (microparticle). Direct conjugation
to a magnetic particle is achieved by use of various chemical
linking groups, as known in the art. Antibody can be coupled to the
microparticles through side chain amino or sulfhydryl groups and
heterofunctional cross-linking reagents. A large number of
heterofunctional compounds are available for linking to entities. A
preferred linking group is 3-(2-pyridyldithio) propionic acid
N-hydroxysuccinimide ester (SPDP) or
4-(N-maleimidomethyl)-cyclohexane-1-carboxylic acid
N-hydroxysuccinimide ester (SMCC) with a reactive sulfhydryl group
on the antibody and a reactive amino group on the magnetic
particle.
[0048] Alternatively, the antibody is indirectly coupled to the
magnetic particles. The antibody may be directly conjugated to a
hapten, and hapten-specific, second stage antibodies are conjugated
to the particles. Suitable haptens include, for examples digoxin,
digoxigenin, FITC, dinitrophenyl, nitrophenyl, avidin, biotin, etc.
Methods for conjugation of the hapten to a protein, i.e. are known
in the art, and kits for such conjugations are commercially
available.
[0049] Target OPC populations are selected by bringing neural or
neural-derived cells into contact with the antibody or reagent that
binds the surface marker. For example, antibody is added to a cell
sample. The amount of antibody or other reagent necessary to bind a
particular cell subset is empirically determined by performing a
test separation and analysis. For example, the cells and
antibody/reagent are incubated for a period of time sufficient for
complexes to form, preferably at least about 5 min, more preferably
at least about 10 min, and usually not more than one hr, more
usually not more than about 30 min. The cells may additionally be
incubated with antibodies or binding molecules specific for cell
surface markers known to be present or absent on OPCs.
[0050] The labeled cells are separated in accordance with the
specific antibody preparation. Fluorochrome labeled antibodies are
useful for FACS separation, magnetic particles for immunomagnetic
selection, particularly high gradient magnetic selection (HGMS),
etc. Exemplary magnetic separation devices are described in WO
90/07380, PCT/US96/00953, and EP 438,520, the disclosures of which
are herein incorporated by reference in their entireties.
[0051] The purified cell population may be collected in any
appropriate medium. Various media are commercially available and
may be used, including Dulbecco's Modified Eagle Medium (DMEM),
Hank's Basic Salt Solution (HBSS), Dulbecco's phosphate buffered
saline (DPBS), RPMI, Iscove's modified Dulbecco's medium (IMDM),
phosphate buffered saline (PBS) with 5 mM EDTA, etc., frequently
supplemented with fetal calf serum (FCS), bovine serum albumin
(BSA), human serum albumin (HSA), etc.
[0052] Populations highly enriched for target OPCs are achieved in
this manner. The desired cells will be 30% or more of the cell
composition, preferably 50% or more (e.g., 60% or more, 70% or
more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or
more) of the cell population, more preferably 90% or more (e.g.,
92% or more, 94% or more, 96% or more, or 98% or more) of the cell
population, and most preferably 95% or more (e.g., 97%, 99%)
(substantially pure) of the cell population. The degree of
enrichment obtained, and actually used, depends on a number of
factors, including, but not limited to, the method of selection,
the method of growth, and/or the dose of the cells that are placed
in culture.
[0053] Isolation, Enrichment, and Selection of Cells
[0054] The invention provides for the isolation and identification
of OPCs. The methods of this invention may be used to isolate
PDGFR.alpha..sup.+ cells from PDGFR.alpha..sup.- cells using an
PDGFR.alpha. antibody or other reagent that specifically binds to
PDGFR.alpha. by combining a population of neural or neural-derived
cells which contains a fraction of OPCs with the antibody or
reagent, and then selecting for PDGFR.alpha..sup.+ cells, to
produce a selected population enriched in PDGFR.alpha..sup.+ OPCs
as compared with the population of neural or neural-derived cells
before selection.
[0055] The population of cells from which OPCs are isolated is
preferably a neural tissue, a population of cells dissociated from
neural tissue, a population of cells that can give rise to neural
cells or neural tissue, or a population of cells in cell culture,
e.g., cells in a neurosphere culture or an adherent neural stem
cell culture. Identification of oligodendrocyte precursor cell
(OPC) involves contacting a population of cells or neural cells (or
tissue which contains neural or neural-derived cells) with a
reagent that binds to cell surface markers expressed by the target
population of OPCs. For example, the method may comprise contacting
a population of neural or neural-derived cells with a reagent that
binds to PDGFR.alpha. (e.g., a monoclonal antibody) and detecting
the contact between the reagent that binds to PDGFR.alpha. and
PDGFR.alpha. on the surface of cells. Target OPCs are included in
the population of cells that reagent binds to the reagent. The
identity of those cells can be confirmed by any assays known on the
art to demonstrate that the cells are, in fact, OPCs, i.e., capable
of proliferation and capable of differentiating into mature
oligodendrocytes.
[0056] The OPCs according to some embodiments may be further
characterized as being immunonegative for CD105 (CD105.sup.-).
Accordingly, the method of identifying, isolating, or enriching
populations of oligodendrocyte precursor cells may additionally
comprise selecting from a population of neural or neural-derived
cells for cells that are immunonegative for CD105 (CD105.sup.-
cells) and eliminating the CD105.sup.+ cells from the population.
Selection of CD105.sup.- cells may then be followed by selecting
from the remaining population for at least one cell that is
immunopositive for PDGFR.alpha. (PDGFR.alpha..sup.+). In the
alternative, the invention provides methods for isolating a
oligodendrocyte precursor cell (OPC), by selecting from a
population of neural or neural-derived cells for cells that are
immunopositive for PDGFR.alpha. (PDGFR.alpha..sup.+), e.g., binds
to monoclonal antibody PDGFR.alpha.; eliminating the
non-immunoreactive (PDGFR.alpha..sup.-) cells from the population;
and selecting from the remaining population for cells that are
immunonegative for CD105 (CD105.sup.-), i.e., eliminating
CD105.sup.+ cells from the population.
[0057] The OPCs according to some embodiments may be further
characterized as being immunopositive for CD133 (CD133.sup.+).
Accordingly, the method of identifying, isolating, or enriching
populations of oligodendrocyte precursor cells may additionally
comprise selecting from a population of neural or neural-derived
cells for cells that are immunopositive for CD133 (CD133.sup.+
cells) and eliminating the CD133.sup.- cells from the population.
Selection of CD133.sup.+ cells may then be followed by selecting
from the remaining population for at least one cell that is
immunopositive for PDGFR.alpha. (PDGFR.alpha..sup.+).
[0058] Accordingly, the invention further provides for the
enrichment of target OPCs from neural tissue or neural stem cell
cultures (e.g., suspension cultures or adherent cultures). The
methods and composition of the invention are thus useful for the
enrichment of target OPC from neural tissue in which stem cells and
progenitor cells occur at low frequency, or may have been depleted,
such as late embryo, juvenile, and adult tissue. Thus, one of skill
in the art can combine a population of neural or neural-derived
cells containing a fraction of target OPCs with a reagent that
specifically binds to, for example, PDGFR.alpha., and then select
for the PDGFR.alpha..sup.+ cells. In this way, the selected
PDGFR.alpha..sup.+ cells are enriched in the fraction of OPC as
compared with the population of neural or neural-derived cells.
According to preferred embodiments, the target OPCs may be
characterized based on a medium to high expression of PDGFR.alpha.
(e.g., PDGFR.alpha..sup.med or PDGFR.alpha..sup.high). For example,
target OPCs are included in the PDGFR.alpha..sup.+ cells sorted
from suspended neurospheres based on medium to high expression
(e.g., PDGFR.alpha..sup.med or PDGFR.alpha..sup.high). Target OPCs
may be further identified by their expression of the markers CD105,
CD133, A2B5, PSA-NCAM, O4, and/or NG2 in accordance with the
present invention.
[0059] Any method for selecting a population of cells on the basis
of cell marker expression known in the art may be used to select
for the OPCs of the present invention. For example, the
identification of PDGFR.alpha..sup.+ and/or CD133.sup.+ target cell
populations may involve contacting a population of neural cells (or
tissue which contains neural or neural derived cells) with a
reagent that binds to PDGFR.alpha. and/or CD133, and detecting the
contact between the reagent that binds to PDGFR.alpha. and/or CD133
and PDGFR.alpha. and/or CD133 on the surface of cells. Target OPCs
are included in the population of those cells to which the reagent
binds. The identity of those cells can be confirmed by assays to
demonstrate that the cells are, in fact, OPCs, i.e., they are
capable of differentiating into mature oligodendrocytes. Use of
traditional techniques for cell sorting, such as by immunoselection
(e.g., fluorescence activated cell separation (FACS)), permits
identification, isolation, and/or enrichment for cells in which
contact between the reagent and the PDGFR.alpha. antigen has been
detected.
[0060] One of skill in the art can introduce an isolated target
OPC(s) to a culture medium; proliferate the isolated target OPC(s)
in culture; culture the progeny of the isolated target OPC(s) under
conditions in which the isolated target OPC(s) differentiates into
oligodendrocytes; and detect the presence of oligodendrocytes. The
presence of oligodendrocytes characterizes the isolated target
OPC(s) as an OPC.
[0061] Any cell markers known in the art may also be used for the
positive and negative selection of OPCs. For example, monoclonal
antibodies (mAb) against human CD45 may be used to exclude blood
cell contamination in fetal tissue. In some cases, mAb against
human CD34 may be used to exclude endothelial cells and
endothelial-neural progenitor complexes. In some cases, antibodies
against human CD24 may be used to exclude those cells that are not
likely to initiate neurospheres. Any of these antibodies may be
used alone, in combination, or sequentially in the methods for
enriching the target cell populations disclosed herein.
[0062] Using the techniques and methods disclosed herein, one of
skill in the art can derive the population of target OPCs by
immunoselection using the appropriate antibody or series of
preferred antibodies. According to some embodiments, the population
of target cells contains at least 30% PDGFR.alpha..sup.+ OPCs,
preferably at least 50-70% PDGFR.alpha..sup.+ OPCs, and more
preferably greater than 90% PDGFR.alpha..sup.+ OPCs (e.g., 92% or
more, 94% or more, 96% or more, or 98% or more). Most preferable
would be a substantially pure population of PDGFR.alpha..sup.+
OPCs, comprising at least 95% PDGFR.alpha..sup.+ OPCs (e.g., 97% or
99%).
[0063] According to some embodiments, the population of target
cells contains at least 30% PDGFR.alpha..sup.+, CD105.sup.- OPCs,
preferably at least 50-70% PDGFR.alpha..sup.+, CD105.sup.- OPCs,
and more preferably greater than 90% PDGFR.alpha..sup.+,
CD105.sup.- OPCs (e.g., 92% or more, 94% or more, 96% or more, or
98% or more). Most preferable would be a substantially pure
population of PDGFR.alpha..sup.+, CD105.sup.- OPCs, comprising at
least 95% PDGFR.alpha..sup.+, CD105.sup.-OPCs (e.g., 97% or
99%).
[0064] According to some embodiments, the population of target
cells contains at least 30% PDGFR.alpha..sup.+, A2B5.sup.- OPCs,
preferably at least 50-70% PDGFR.alpha..sup.+, A2B5.sup.- OPCs, and
more preferably greater than 90% PDGFR.alpha..sup.+, A2B5.sup.-
OPCs (e.g., 92% or more, 94% or more, 96% or more, or 98% or more).
Most preferable would be a substantially pure population of
PDGFR.alpha..sup.+, A2B5.sup.- OPCs, comprising at least 95%
PDGFR.alpha..sup.+, A2B5.sup.- OPCs (e.g., 97% or 99%). According
to some embodiments, the population of target cells is additionally
immunonegative for CD105 (CD105.sup.-).
[0065] According to some embodiments, the population of target
cells contains at least 30% PDGFR.alpha..sup.+, A2B5.sup.lo/- OPCs,
preferably at least 50-70% PDGFR.alpha..sup.+, A2B5.sup.lo/- OPCs,
and more preferably greater than 90% PDGFR.alpha..sup.+,
A2B5.sup.lo/- OPCs (e.g., 92% or more, 94% or more, 96% or more, or
98% or more). Most preferable would be a substantially pure
population of PDGFR.alpha..sup.+, A2B5.sup.lo/- OPCs, comprising at
least 95% PDGFR.alpha..sup.+, A2B5.sup.lo/- OPCs (e.g., 97% or
99%). According to some embodiments, the population of target cells
is additionally immunonegative for CD105 (CD105.sup.-).
[0066] According to some embodiments, the population of target
cells contains at least 30% PDGFR.alpha..sup.med/high, A2B5.sup.-
OPCs, preferably at least 50-70% PDGFR.alpha..sup.med/high,
A2B5.sup.- OPCs, and more preferably greater than 90%
PDGFR.alpha..sup.med/high, A2B5.sup.- OPCs (e.g., 92% or more, 94%
or more, 96% or more, or 98% or more). Most preferable would be a
substantially pure population of PDGFR.alpha..sup.med/high,
A2B5.sup.- OPCs, comprising at least 95% PDGFR.alpha..sup.med/high,
A2B5.sup.- OPCs (e.g., 97% or 99%). According to some embodiments,
the population of target cells is additionally immunonegative for
CD105 (CD105.sup.-).
[0067] According to some embodiments, the population of target
cells contains at least 30% PDGFR.alpha..sup.med/high, A2B5.sup.-
OPCs, preferably at least 50-70% PDGFR.alpha..sup.med/high,
A2B5.sup.lo/- OPCs, and more preferably greater than 90%
PDGFR.alpha..sup.med/high, A2B5.sup.lo/- OPCs (e.g., 92% or more,
94% or more, 96% or more, or 98% or more). Most preferable would be
a substantially pure population of PDGFR.alpha..sup.med/high,
A2B5.sup.lo/- OPCs, comprising at least 95%
PDGFR.alpha..sup.med/high, A2B5.sup.- OPCs (e.g., 97% or 99%).
According to some embodiments, the population of target cells is
additionally immunonegative for CD105 (CD105.sup.-).
[0068] According to some embodiments, the population of target
cells contains at least 30% PDGFR.alpha..sup.+, PSA-NCAM.sup.-
OPCs, preferably at least 50-70% PDGFR.alpha..sup.+, PSA-NCAM.sup.-
OPCs, and more preferably greater than 90% PDGFR.alpha..sup.+,
PSA-NCAM.sup.- OPCs (e.g., 92% or more, 94% or more, 96% or more,
or 98% or more). Most preferable would be a substantially pure
population of PDGFR.alpha..sup.+, PSA-NCAM.sup.- OPCs, comprising
at least 95% PDGFR.alpha..sup.+, PSA-NCAM.sup.- OPCs (e.g., 97% or
99%). According to some embodiments, the population of target cells
is additionally immunonegative for CD105 (CD105.sup.-).
[0069] According to some embodiments, the population of target
cells contains at least 30% PDGFR.alpha..sup.+, PSA-NCAM.sup.lo/-
OPCs, preferably at least 50-70% PDGFR.alpha..sup.+,
PSA-NCAM.sup.lo/- OPCs, and more preferably greater than 90%
PDGFR.alpha..sup.+, PSA-NCAM.sup.lo/- OPCs (e.g., 92% or more, 94%
or more, 96% or more, or 98% or more). Most preferable would be a
substantially pure population of PDGFR.alpha..sup.+,
PSA-NCAM.sup.lo/- OPCs, comprising at least 95% PDGFR.alpha..sup.+,
PSA-NCAM.sup.lo/- OPCs (e.g., 97% or 99%). According to some
embodiments, the population of target cells is additionally
immunonegative for CD105 (CD105.sup.-).
[0070] According to some embodiments, the population of target
cells contains at least 30% PDGFR.alpha..sup.med/high,
PSA-NCAM.sup.- OPCs, preferably at least 50-70%
PDGFR.alpha..sup.med/high, PSA-NCAM.sup.- OPCs, and more preferably
greater than 90% PDGFR.alpha..sup.med/high, PSA-NCAM.sup.- OPCs
(e.g., 92% or more, 94% or more, 96% or more, or 98% or more). Most
preferable would be a substantially pure population of
PDGFR.alpha..sup.med/high, PSA-NCAM.sup.- OPCs, comprising at least
95% PDGFR.alpha..sup.med/high, PSA-NCAM.sup.- OPCs (e.g., 97% or
99%). According to some embodiments, the population of target cells
is additionally immunonegative for CD105 (CD105.sup.-).
[0071] According to some embodiments, the population of target
cells contains at least 30% PDGFR.alpha..sup.med/high,
PSA-NCAM.sup.lo/- OPCs, preferably at least 50-70%
PDGFR.alpha..sup.med/high, PSA-NCAM.sup.lo/- OPCs, and more
preferably greater than 90% PDGFR.alpha..sup.med/high,
PSA-NCAM.sup.lo/- OPCs (e.g., 92% or more, 94% or more, 96% or
more, or 98% or more). Most preferable would be a substantially
pure population of PDGFR.alpha..sup.med/high, PSA-NCAM.sup.lo/-
OPCs, comprising at least 95% PDGFR.alpha..sup.med/high,
PSA-NCAM.sup.lo/- OPCs (e.g., 97% or 99%). According to some
embodiments, the population of target cells is additionally
immunonegative for CD105 (CD105.sup.-).
[0072] According to some embodiments, the population of target
cells contains at least 30% PDGFR.alpha..sup.+, CD133.sup.+,
A2B5.sup.lo/- OPCs, preferably at least 50-70% PDGFR.alpha..sup.+,
CD133.sup.+, A2B5.sup.lo/- OPCs, and more preferably greater than
90% PDGFR.alpha..sup.+, CD133.sup.+, A2B5.sup.lo/- OPCs (e.g., 92%
or more, 94% or more, 96% or more, or 98% or more). Most preferable
would be a substantially pure population of PDGFR.alpha..sup.+,
CD133.sup.+, A2B5.sup.lo/- OPCs, comprising at least 95%
PDGFR.alpha..sup.+, CD133.sup.+, A2B5.sup.lo/- OPCs (e.g., 97%,
99%). According to some embodiments, the population of target cells
is additionally immunonegative for CD105 (CD105.sup.-).
[0073] According to some embodiments, the population of target
cells contains at least 30% PDGFR.alpha..sup.+, CD133.sup.+,
PSA-NCAM.sup.lo/- OPCs, preferably at least 50-70%
PDGFR.alpha..sup.+, CD133.sup.+, PSA-NCAM.sup.lo/- OPCs, and more
preferably greater than 90% PDGFR.alpha..sup.+, CD133.sup.+,
PSA-NCAM.sup.lo/- OPCs (e.g., 92% or more, 94% or more, 96% or
more, or 98% or more). Most preferable would be a substantially
pure population of PDGFR.alpha..sup.+, CD133.sup.+,
PSA-NCAM.sup.lo/- OPCs, comprising at least 95% PDGFR.alpha..sup.+,
CD133.sup.+, PSA-NCAM.sup.lo/- OPCs (e.g., 97%, 99%). According to
some embodiments, the population of target cells is additionally
immunonegative for CD105 (CD105.sup.-).
[0074] According to some embodiments, the population of target
cells contains at least 30% PDGFR.alpha..sup.+, A2B5.sup.lo/-,
PSA-NCAM.sup.lo/- OPCs, preferably at least 50-70%
PDGFR.alpha..sup.+, A2B5.sup.lo/-, PSA-NCAM.sup.lo/- OPCs, and more
preferably greater than 90% PDGFR.alpha..sup.+, A2B5.sup.lo/-,
PSA-NCAM.sup.lo/- OPCs (e.g., 92% or more, 94% or more, 96% or
more, or 98% or more). Most preferable would be a substantially
pure population of PDGFR.alpha..sup.+, A2B5.sup.lo/-,
PSA-NCAM.sup.lo/- OPCs, comprising at least 95% PDGFR.alpha..sup.+,
A2B5.sup.lo/-, PSA-NCAM.sup.lo/- OPCs (e.g., 97%, 99%). According
to some embodiments, the population of target cells is additionally
immunonegative for CD105 (CD105.sup.-).
[0075] According to some embodiments, the population of target
cells contains at least 30% PDGFR.alpha..sup.med/high,
A2B5.sup.lo/-, PSA-NCAM.sup.lo/- OPCs, preferably at least 50-70%
PDGFR.alpha..sup.med/high, A2B5.sup.lo/-, PSA-NCAM.sup.lo/- OPCs,
and more preferably greater than 90% PDGFR.alpha..sup.med/high,
A2B5.sup.lo/-, PSA-NCAM.sup.lo/- OPCs (e.g., 92% or more, 94% or
more, 96% or more, or 98% or more). Most preferable would be a
substantially pure population of PDGFR.alpha..sup.med/high,
A2B5.sup.lo/-, PSA-NCAM.sup.lo/- OPCs, comprising at least 95%
PDGFR.alpha..sup.med/high, A2B5.sup.lo/-, PSA-NCAM.sup.lo/- OPCs
(e.g., 97%, 99%). According to some embodiments, the population of
target cells is additionally immunonegative for CD105
(CD105.sup.-).
[0076] According to some embodiments, the population of target
cells contains at least 30% PDGFR.alpha..sup.+, O4.sup.- OPCs,
preferably at least 50-70% PDGFR.alpha..sup.+, O4.sup.- OPCs, and
more preferably greater than 90% PDGFR.alpha..sup.+, O4.sup.- OPCs
(e.g., 92% or more, 94% or more, 96% or more, or 98% or more). Most
preferable would be a substantially pure population of
PDGFR.alpha..sup.+, O4.sup.- OPCs, comprising at least 95%
PDGFR.alpha..sup.+, O4.sup.- OPCs (e.g., 97%, 99%). According to
some embodiments, the population of target cells is additionally
immunonegative for CD105 (CD105.sup.-). The degree of enrichment
obtained, and actually used, depends on a number of factors,
including the method of selection, the method of growth, and/or the
dose of the cells that are placed in culture.
[0077] Cryopreservation and Handling
[0078] According to some embodiments, the OPCs of the present
embodiments may be cryopreserved according to routine procedures.
In some embodiments, cryopreserving involves freezing about one to
ten million cells in "freeze" medium, which may comprise
proliferation medium and antioxidants such as NAC (0.1 to 2 mM;
e.g., 0.5 mM, 1 mM, etc.). Proliferation medium is preferably
absent the growth factor mitogens. For example, suspended cells may
be centrifuged and any growth medium is aspirated and replaced with
freeze medium. Cells may then be slowly frozen, by, e.g., placing
in a container at -80.degree. C. or frozen in liquid nitrogen.
Cells are thawed by swirling in a 37.degree. C. bath, resuspended
in fresh proliferation medium, and grown as usual.
[0079] According to some embodiments, the OPCs of the present
embodiments may be cryopreserved in a ready to use format (such as
a pharmaceutical grade vial or container). In some embodiments, the
OPCs are thawed and cultured prior to use. In some embodiments, the
OPCs are thawed and cultured in suspension prior to use. In some
embodiments, the OPCs are thawed and cultured on an adherent
substrate prior to use. The period for culturing after thawing may
be 1 to 24 hours. In some embodiments, the period for culture after
thawing may be from 1 to 2 days.
[0080] According to some embodiments, the OPCs of the present
invention may be held in a suspension culture format. According to
some embodiments, the OPCs of the present invention may be held in
a suspension culture format after detachment from a culture plate
(e.g., post trypsin treatment). For example, adherent OPCs are
detached by treatment with trypsin and are transferred to a
suspension culture medium. The period of time in which the OPCs are
held in suspension may be referred to as the "hold" period. The
hold period in suspension is advantageous for at least the
following 3 reasons: 1) would allow cells to recover from a
potentially damaging enzyme treatment prior to transplantation
and/or cryopreservation; 2) it would introduce more flexibility in
animal surgery scheduling and 3) would make shipment of
ready-to-transplant OPCs to an off-site location (laboratory or
clinic) possible. According to some embodiments, the hold period
may be 2, 4, 6, 8, 12, 18, or 24 hours. According to some
embodiments, the hold period may be 1, 2, 3, 4, 5, 6, 7, 8, 9, or
10 days.
[0081] Tissue Source
[0082] Any suitable tissue source may be used to derive the OPCs of
this invention. The adult human CNS has been shown to contain
oligodendrocyte precursor cells that are capable of proliferating,
and which could mature into myelinating oligodendrocytes under the
appropriate conditions. Accordingly, the population of cells can be
derived from late embryo, juvenile, or adult mammalian CNS tissue,
or it may be derived from existing cultures of neural stem cells,
as described in Weiss, U.S. Pat. No. 5,750,376, or Johe, U.S. Pat.
No. 5,753,506. The OPCs may also be obtained from any tissue or
cellular source that is capable of giving rise to neural tissue. In
one preferred embodiment, the OPCs are human.
[0083] OPCs may be been isolated from neural or neural-derived
cells of several mammalian species including, but not limited to,
mice, rats, pigs, non-human primates, and humans. Neural or
neural-derived cells may be obtained from embryonic, fetal,
post-natal, juvenile, or adult neural tissue, which includes brain
and spinal cord. For example, neural or neural-derived cells may be
obtained from the cerebral cortex, cerebellum, midbrain, brainstem,
spinal cord, and ventricular tissue, as well as areas of the PNS
including the carotid body and the adrenal medulla. Other preferred
areas include regions in the basal ganglia, preferably the
striatum, which consists of the caudate and putamen, or various
cell groups such as the globus pallidus, the subthalamic nucleus,
the nucleus basalis, the substantia nigra pars compacta, as well as
from ventricular tissue found lining CNS ventricles, including the
subependyma. The subventricular zone and ventral neuroepithelium
are preferred source of OPCs in the adult animal.
[0084] In addition to OPCs, a population of cells exists within the
adult CNS that exhibit stem cell properties in their ability to
self-renew and to produce the differentiated mature cell phenotypes
of the adult CNS such as oligodendrocytes. These stem cells are
found throughout the CNS, particularly in the subventricular region
and the dentate gyrus of the hippocampus, and represent a source of
neural or neural derived cells from which the target OPCs may be
isolated. Neural stem cells have also been isolated from a variety
of adult CNS ventricular regions, including the frontal lobe, conus
medullaris, thoracic spinal cord, brain stem, and hypothalamus.
[0085] Growth factor-responsive stem cells can be isolated from
many regions of the neuraxis and at different stages of
development, of murine, rodent, mammalian, and human CNS tissue.
These cells vary in their response to growth factors such as EGF,
basic FGF (bFGF, FGF-2) and transforming growth factor alpha
(TGF.alpha.) and can be maintained and expanded in culture in an
undifferentiated state for long periods of time. (See, e.g.
WO93/01275 and WO94/16788, incorporated herein by reference).
[0086] Proliferation
[0087] OPCs can be induced to proliferate either by culturing the
cells in suspension or on an adherent substrate. See, e.g., U.S.
Pat. Nos. 5,750,376 and 5,753,506 (both incorporated herein by
reference in their entirety), and medium described therein. Both
allografts and autografts are contemplated for transplantation
purposes.
[0088] Typically, OPCs of the present embodiments are cultured in a
medium that permits their growth and proliferation. The culture in
which the isolated OPCs proliferates can be a serum-free medium
containing one or more predetermined growth factors effective for
inducing proliferation. The culture medium may be supplemented with
a growth factor selected from platelet-derived growth factor
(PDGF), epidermal growth factor (EGF), basic fibroblast growth
factor (FGF-2; bFGF), NT3, IGF1 or combinations thereof. The
culture medium may be further supplemented with N2 and B27. The
conditions in which the OPCs differentiate to oligodendrocytes
include culturing the OPC progeny on a laminin or laminin plus
fibronectin-coated surface in culture medium containing fetal
bovine serum (FBS) or T3 (triiodothyronine) without EGF, bFGF,
PDGF, NT3, IGF1 or LIF.
[0089] According to some embodiments, the OPCs of the present
embodiments may be passaged from 1 to 20 times (e.g., 1, 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20
times) post isolation from the primary tissue source and may be
induced to proliferate by culturing the cells in suspension or on
an adherent substrate. Passaging (a.k.a, subculturing or splitting)
typically involves detaching cells from the surface of the primary
culture vessel by trypsinization or mechanical means. The resultant
cell suspension is then subdivided, or reseeded, into fresh
cultures. Secondary cultures are checked for growth and fed
periodically, and may be subsequently subcultured to produce
tertiary cultures and so on. The time between passaging of cells
varies and depends on the growth rate.
[0090] The proliferation medium can be any medium known in the art
to induce proliferation of the OPCs without inducing their
differentiation. Example 3 provided herein provides an exemplary
medium for proliferating the OPCs of the present embodiments. Cell
passage or splitting is necessary to maintain cells in exponential
growth. Methods for passaging or splitting cells are well known in
the art. The OPCs may be passaged using any known method known in
the art.
[0091] Differentiation
[0092] When OPCs are cultured under conditions that allow
differentiation, progenitor cells differentiate to
oligodendrocytes. Differentiation of the cells can be induced by
any method known in the art, which include the liberation of
inositol triphosphate and intracellular Ca.sup.2+, liberation of
diacyl glycerol, and the activation of protein kinase C and other
cellular kinases, and the like. Treatment with phorbol esters,
differentiation-inducing growth factors, hormones and other
chemical signals can induce differentiation. Differentiation can be
induced by growth factor exhaustion, for example, by removal of
mitogens, by leaving the cells in culture without media renewal, or
by absence of passaging.
[0093] The induction of proliferation (and differentiation) of the
OPCs can be done either by culturing the cells in suspension or on
a substrate onto which they can adhere. Alternatively,
proliferation and differentiation of OPCs can be induced, under
appropriate conditions, in the host in the following combinations:
(1) proliferation and differentiation in vitro, then
transplantation, (2) proliferation in vitro, transplantation, then
further proliferation and differentiation in vivo, (3)
proliferation in vitro, transplantation and differentiation in
vivo, and (4) proliferation and differentiation in vivo.
Proliferation and differentiation in vivo or in situ can involve a
non-surgical approach that coaxes OPCs to proliferate in vivo with
pharmaceutical manipulation. Such methods involving the
transplantation of OPCs are discussed in further detail below.
[0094] Use of Purified Stem Cell/Progenitor Cells.
[0095] The target OPC populations identified using the methods
described herein are useful in a variety of ways, including for
drug screening, diagnostics, transplantation, and treatment. The
OPCs may be used to reconstitute a host whose cells have been lost
through disease or injury. Genetic diseases associated with cells
may be treated by genetic modification of autologous or allogeneic
OPCs to correct a genetic defect or treat to protect against
disease. Alternatively, normal allogeneic OPCs may be transplanted.
Diseases other than those associated with cells may also be
treated, where the disease is related to the lack of a particular
secreted product such as hormone, enzyme, growth factor, or the
like.
[0096] CNS disorders encompass numerous afflictions such as
neurodegenerative diseases (e.g. Alzheimer's and Parkinson's),
acute brain injury (e.g. stroke, ischemia, head injury, cerebral
palsy) and a large number of CNS dysfunctions (e.g. depression,
epilepsy, and schizophrenia). In recent years neurodegenerative
disease has become an important concern due to the expanding
elderly population which is at greatest risk for these disorders.
These diseases, which include, for example, Alzheimer's Disease,
Multiple Sclerosis (MS), Huntington's Disease, Amyotrophic Lateral
Sclerosis, and Parkinson's Disease, have been linked to the
degeneration of neural cells in particular locations of the CNS,
leading to the inability of these cells or the brain region to
carry out their intended function. By providing for maturation,
proliferation and differentiation into oligodendrocytes through
specific different growth factors, the oligodendrocyte progenitor
cells may be used as a source of oligodendrocytes.
[0097] The target OPC populations may also be used in the isolation
and evaluation of factors associated with the differentiation and
maturation of cells. Thus, the cells may be used in assays to
determine the activity of media, such as conditioned media,
evaluate fluids for growth factor activity, involvement with
dedication of lineages, or the like.
[0098] The target OPC populations may be frozen at liquid nitrogen
temperatures and stored for long periods of time, being thawed and
capable of being reused. The cells will usually be stored in 7.5%
DMSO and 4% HSA (human serum albumin). Once thawed, the cells may
be expanded by use of growth factors or cells associated with OPC
proliferation and differentiation.
[0099] Transplantation
[0100] The target OPC populations obtained from neural cell
populations or neural tissue may be introduced (e.g., by
transplantation) into a mammal, particularly to compensate for lost
or dysfunctional oligodendrocytes. The mammal is preferably a
human, canine, feline, rodent, sheep, goat, cattle, horse, pig, or
non-human primate. Most preferably, the mammal is human. Since OPCs
may be cultured from brain tissues from mammals of any age,
including adults, it is preferable to grow neural stem cells using
a mammal's own tissue for autologous transplantation. Allogeneic
and xenogeneic transplantations are also possible, particularly
when the transplantation site is in the brain or eye, where
immunologic rejection is less severe due to the blood-brain or
blood-retina barrier.
[0101] In some embodiments, the OPCs of the present embodiments are
transplanted at a dose of at least on the order of greater than
1.times.10.sup.20 total nucleated cells, or at least on the order
of 10.sup.19, or 10.sup.18, or 10.sup.17, or 10.sup.16, or
10.sup.15, or 10.sup.14, or 10.sup.13, or 10.sup.12, or 10.sup.11,
or 10.sup.10, or 10.sup.9, or 10.sup.8, or 10.sup.7, or 10.sup.6,
or 10.sup.5 cells. In some embodiments, the OPCs of the present
embodiments may be transplanted at a dose of between
1.times.10.sup.6 to 1.times.10.sup.12, 1.times.10.sup.6 to
1.times.10.sup.9, 1.times.10.sup.8 to 1.times.10.sup.10,
1.times.10.sup.9 to 1.times.10.sup.12, and 1.times.10.sup.9 to
1.times.10.sup.10 cells. In some embodiments, the dosage of cells
is prepared in a sealed, pharmaceutical quality vial in a format
that is ready to administer to a subject.
[0102] It is also that the target OPCs may be transplanted into a
mammal and induced to form oligodendrocytes in vivo. Thus, target
OPC populations may be expanded in culture using established
methods, transplanted into the mammal, and contacted in vivo with
the oligodendrocyte promoting factor to produce oligodendrocytes.
Optionally, the transplanted OPCs can be expanded again in vivo by
administering to the mammal any biological agents known to increase
the number of OPCs.
[0103] According to some embodiments, the OPCs of the present
invention are transplanted in between 1 to 5 days post passaging,
preferably between 1 to 2 days past passaging. The OPCs of the
present embodiments may be transplanted as clusters or
disassociated cell suspensions. Engraftment data (not shown) using
cells obtained in this manner are healthy and result in graft
containing high number of myelinating oligodendrocytes. According
to some embodiments, the OPCs of the present embodiments may be
held in suspension between 10 minutes to 5 days (e.g., 30 minutes,
1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48
hours, 3 days, 4 days etc.) post passaging in a pharmaceutical
quality vial in a format that is ready to administer to a subject.
In some the OPCs of the present embodiments may be held in
suspension at a dose of at least on the order of greater than
1.times.10.sup.20 total nucleated cells, or at least on the order
of 10.sup.19, or 10.sup.18, or 10.sup.17, or 10.sup.16, or
10.sup.15, or 10.sup.14, or 10.sup.13, or 10.sup.12, or 10.sup.11,
or 10.sup.10, or 10.sup.9, or 10.sup.8, or 10.sup.7, or 10.sup.6,
or 10.sup.5 cells. In some embodiments, the OPCs of the present
embodiments may be held in suspension at a dose of between
1.times.10.sup.6 to 1.times.10.sup.12, 1.times.10.sup.6 to
1.times.10.sup.9, 1.times.10.sup.8 to 1.times.10.sup.10,
1.times.10.sup.9 to 1.times.10.sup.12, and 1.times.10.sup.9 to
1.times.10.sup.10 cells. In some embodiments, the dosage of cells
is prepared in a sealed, pharmaceutical quality vial in a format
that is ready to administer to a subject.
[0104] The oligodendrocyte promoting factors or the biological
agents may be administered by any suitable route established in the
art, including, for example, orally, topically, rectally,
vaginally, intrathecally, intravascularly, intravenously,
intramuscularly, intraperitoneally, transdermally, intradermally,
subcutaneously, nasally or by inhalation. The route of
administration depends primarily on the nature of the agent. For
example, GM-CSF is capable of crossing the blood-brain barrier,
hence it can be administered systemically as well as into the
brain. The preferred method of administration is injection (e.g.,
with a needle or a catheter) or infusion.
[0105] The target OPCs may be transplanted "naked" into patients
according to conventional techniques, into the CNS as described,
for example, in U.S. Pat. Nos. 5,082,670 and 5,618,531, the
disclosures of which are incorporated herein by reference, or into
any other suitable site in the body. In some embodiments, the OPCs
are transplanted directly into the CNS. Parenchymal and intrathecal
sites are contemplated. It will be appreciated that the exact
location in the CNS will vary according to the disease state.
[0106] According to some embodiments, the OPCs may be allowed to
aggregate prior to implantation, or may be applied directly as
dissociated single cells. When using OPC aggregates,
transplantation is preferably performed using small sized
aggregates approximately 10-500 .mu.m in diameter, preferably 40-50
.mu.m in diameter. Preferably, from about 1 million cells to about
1 billion cells are transplanted. For example, a total of about 1
million, about 5 million, about 10 million, about 25 million, about
50 million, about 75 million, about 100 million, about 250 million,
about 500 million, about 750 million, or about 1 billion cells are
transplanted.
[0107] The OPCs are preferably introduced into the brain or spinal
cord of the mammal, particularly at sites where oligodendrocytes
are insufficient and/or dysfunctional, for example, around axons
that have been demyelinated. In humans, areas of demyelination are
generally associated with plaque like structures, which can be
visualized with magnetic resonance imaging (MRI). The cells may
also be transplanted into other areas of the central nervous
system. One particularly useful approach is to transplant into the
"minor image" location of a target lesion in the other hemisphere,
since cells are known to efficiently migrate to the corresponding
location in the opposite hemisphere through the corpus
callosum.
[0108] According to some embodiments, the OPCs are introduced
directly to regions of the brain or spinal cord. Directed
introduction of the OPCs may be carried out using any methods known
in the art. Thus, according to some embodiments, the OPCs are
introducted to the target brain region via injection. Preferably,
the OPCs are introduced into brain regions that are heavily
myelinated (rich in white matter). The fimbria is a prominent band
of white matter along the medial edge of the hippocampus. White
matter forms the bulk of the deep parts of the brain and the
superficial parts of the spinal cord. The corpus callosum is the
largest white matter structure in the brain that connects the left
and right cerebral hemispheres. In some embodiments, the target
brain regions include the fimbria, callosum, cerebral peduncle,
internal capsule, spinal cord, brain stem, motor cortex, olfactory
cortex, somatosensory cortex, anterior cingulate gyrus, the
Inferior temporal lobe, and the Dorsolateral prefrontal cortex, and
medulla oblongata.
[0109] Aggregates of gray matter such as the basal ganglia (caudate
nucleus, putamen, globus pallidus, subthalamic nucleus, nucleus
accumbens) and brain stem nuclei (red nucleus, substantia nigra,
cranial nerve nuclei) are spread within the cerebral white matter.
Such areas are also target brain regions. Target brain regions
include, but are not limited to, the telencephalon (cerebral
hemispheres, forebrain), diencephalon (thalamus, hypothalamus,
epithalamus, prethalamus or subthalamus and pretectum),
mesencephalon (midbrain), cerebellum, pons, and medulla oblongata.
The mesencephalon includes the tectum (inferior colliculi and
superior colliculi) and cerebral peduncle (midbrain tegmentum, crus
cerebri, substantia nigra). The substantia nigra is part of the
basal ganglia; the other parts of the basal ganglia include the
striatum (caudate nucleus, putamen, and nucleus accumbens), globus
pallidus, and subthalamic nucleus. Target brain regions may include
the brain stem, striatum, internal capsule, caudate nucleus and
putamen.
[0110] Genetic Modification of OPCs.
[0111] The OPCs of the present embodiments may be genetically
modified to provide a therapeutically effective biologically active
molecule. In some embodiments, the genetically modified OPCs may be
transplanted or introduced to a subject in need thereof as
described above.
[0112] In some embodiments, the OPCs of the present embodiments may
be genetically modified to express a particular form of Myelin
Proteolipid Protein (PLP), such as in the case of autologous
transplant. In addition, the OPCs of the present embodiments may be
genetically modified to express one or more of the following:
telomerase (to prevent telomere erosion), growth factors,
morphogens, enzymes, anti-apoptotic genes (e.g., sonic hedgehog,
FGF2, NT3, BDNF, PDGF, IGF, NGF), arylsuphatase A (metachromatic
leukodystrophy), galactosylceramidase (krabbe's), superoxide
dismutase and other proteins involved in antioxidant defense, and
Bcl-XL.
[0113] The OPCs described herein can be genetically engineered or
modified according to known methodology. The term "genetic
modification" refers to the stable or transient alteration of the
genotype of a cell by intentional introduction of exogenous DNA.
DNA may be synthetic, or naturally derived, and may contain genes,
portions of genes, or other useful DNA sequences. The term "genetic
modification" is not meant to include naturally occurring
alterations such as that which occurs through natural viral
activity, natural genetic recombination, or the like.
[0114] A gene of interest (i.e., a gene that encodes a biologically
active molecule) can be inserted into a cloning site of a suitable
expression vector by using standard techniques. These techniques
are well known to those skilled in the art. See, e.g., WO 94/16718,
incorporated herein by reference.
[0115] The expression vector containing the gene of interest may
then be used to transfect the desired cell line. Standard
transfection techniques such as calcium phosphate co-precipitation,
DEAE-dextran transfection, electroporation, biolistics, or viral
transfection may be utilized. Commercially available mammalian
transfection kits may be purchased from e.g., Stratagene. Human
adenoviral transfection may be accomplished as described in Berg et
al. Exp. Cell Res., 192, pp. (1991). Similarly, lipofectamine-based
transfection may be accomplished as described in Cattaneo, Mol.
Brain. Res., 42, pp. 161-66 (1996).
[0116] A wide variety of host/expression vector combinations may be
used to express a gene encoding a biologically active molecule of
interest. See, e.g., U.S. Pat. No. 5,545,723, herein incorporated
by reference, for suitable cell-based production expression
vectors.
[0117] Increased expression of the biologically active molecule can
be achieved by increasing or amplifying the transgene copy number
using amplification methods well known in the art. Such
amplification methods include, e.g., DHFR amplification (see, e.g.,
Kaufman et al., U.S. Pat. No. 4,470,461) or glutamine synthetase
("GS") amplification (see, e.g., U.S. Pat. No. 5,122,464, and
European published application EP 338,841), all herein incorporated
by reference.
[0118] Any expression vector known in the art may be used to
express the biologically active molecule. In some embodiments, a
lentivirally-derived vector may be particularly useful for the
delivery of exogenous genes. Such lentiviral vectors are known in
the art. In some embodiments, exogenous genes may need to be
introduced into the target OPCs expression. Such genes may be under
the control of a constitutive or inducible promoters to effect
optimal co-expression. Exogenous DNA may be introduced to a
precursor cell by viral vectors (retrovirus, modified herpes viral,
herpes-viral, adenovirus, adeno-associated virus, lentivirus and
the like) or direct DNA transfection (lipofection, CaPO.sub.4
transfection, DEAE-dextran, electroporation, and the like).
[0119] The OPCs of the present embodiments may be genetically
modified for drug screening purposes or for the purposes of
detecting cells of the oligodendrocyte or OPC lineage. In some
embodiments, OPCs may be genetically modified with one or more
reporter genes. Such reporter genes include fluorescent proteins
(e.g., green fluorescent proteins, yellow fluorescent proteins,
blue fluorescent proteins, cyan fluorescent proteins, etc.),
DsRed2, mCherry, tdTomato, and AmCyan1. Preferred promoters include
one or more of the following promoters: MBP, CNPase, Olig2, Sox10,
Plp, and PDGFR promoter.
[0120] Treatment
[0121] A number of neurologic diseases are associated with defects
in myelination and in neuronal homeostasis and function. Examples
of these demyelinating diseases or conditions or dysmyelinating
disorders include, but are not limited to, multiple sclerosis
(including the relapsing and chronic progressive forms of multiple
sclerosis, acute multiple sclerosis, neuromyelitis optica (Devic's
disease)), diffuse cerebral sclerosis (including Shilder's
encephalitis periaxialis diffusa and Balo's concentric sclerosis).
Demyelinating diseases also include a variety of diseases wherein
demyelination is caused by viral infections, vaccines, spinal cord
injury, and genetic disorders. Examples of these demyelinating
diseases or dysmyelinating disorders include, but are not limited
to, acute disseminated encephalomyelitis (occurring after measles,
chickenpox, rubella, influenza or mumps; or after rabies or
smallpox vaccination), necrotizing hemorrhagic encephalitis
(including hemorrhagic leukoencephalitis), and leukodystrophies
(including Krabbe's globboid leukodystrophy, metachromatic
leukodystrophy, adrenoleukodystrophy, adrenomyeloneuropathy,
adrenomyeloneuropathy, radiation induced myelination disorders,
transverse myelitits, Pelizaeus-Merzbacher disease, Canavan's
disease and Alexander's disease). The demyelinating disease or
dysmyelinating disorders is preferably multiple sclerosis, cerebral
palsy, diffuse cerebral sclerosis, or Pelizaeus-Merzbacher disease
(PMD), and, most preferably, Pelizaeus-Merzbacher disease.
[0122] The cells and methods of this invention may be useful in the
treatment of various neurodegenerative diseases, demyelinating
diseases and/or dysmyelinating disorders. It is contemplated that
the cells will replace diseased, damaged or lost tissue in the
host. Alternatively, the transplanted tissue may augment the
function of the endogenous affected host tissue.
[0123] According to some embodiments, there is provided a method of
enhancing oligodendrocyte production in vivo by administering the
target OPCs to a mammal under conditions that result in
oligodendrocyte formation. The resultant oligodendrocytes are
capable of myelinating (or remyelinating) demyelinated neurons in
the mammal, whereby dysmyelinating disorders and/or demyelinating
diseases in the mammal can be treated or ameliorated.
[0124] According to some embodiments, there is provided a method of
enhancing oligodendrocyte production in vivo by identifying and
isolating target populations of OPCs, culturing the target
populations of OPCs under conditions to promote their
proliferations, and administering the OPCs to a mammal under
conditions that result in oligodendrocyte formation. The resultant
oligodendrocytes are capable of myelinating (or remyelinating)
demyelinated neurons in the mammal, whereby dysmyelinating
disorders and/or demyelinating diseases in the mammal can be
treated or ameliorated.
[0125] According to some embodiments, there is provided a method of
enhancing oligodendrocyte production in vivo by identifying and
isolating target populations of OPCs, culturing the target
populations of OPCs under conditions to promote their
proliferations, differentiating the target populations of OPCs into
oligodendrocytes, and administering the oligodendrocytes to a
mammal under conditions that result in oligodendrocyte engraftment.
The resultant oligodendrocytes are capable of myelinating (or
remyelinating) demyelinated neurons in the mammal, whereby
dysmyelinating disorders and/or demyelinating diseases in the
mammal can be treated or ameliorated.
[0126] According to some embodiments, there is provided a method of
enhancing oligodendrocyte production in vivo by identifying and
isolating target populations of OPCs and administering target OPCs
to a mammal under conditions that result in oligodendrocyte
engraftment. The resultant oligodendrocytes are capable of
myelinating (or remyelinating) demyelinated neurons in the mammal,
whereby dysmyelinating disorders and/or demyelinating diseases in
the mammal can be treated or ameliorated.
[0127] Drug Screening
[0128] The OPCs of the present invention may also be used in a
method of drug screening or drug discovery. Any cell-based drug
screening protocol known in the art may be used in conjunction with
the OPCs of the present invention. A wide variety of assays may be
used for this purpose, including toxicology testing; immunoassays
for protein binding; determination of cell growth, differentiation
and functional activity; production of hormones; and the like. The
assays may be performed in vitro, in situ, in vivo, and ex vivo.
For example, the OPCs of the present invention may be used in a
drug screening method comprising the steps of a) selecting from an
enriched target OPC population, b) engrafting a non-human mammal
with the resulting enriched population; c) administering a test
compound to the non-human mammal; and d) comparing the effect of
administration of said test compound in the engrafted mammal with a
control non-human mammal not administered said test compound.
[0129] According to some embodiments, the present invention
provides a method of screening for compounds that affect a
biological function of an enriched population of target
oligodendrocyte precursor cells comprising: (a) contacting an
enriched population of target oligodendrocyte precursor cells
obtained by the method of claim 1 with a test compound; and (b)
detecting a change in a biological function of the oligodendrocyte
precursor cells. The change in biological function may include, but
is not limited to, changes in one or more of the following:
myelination, differentiation into oligodendrocytes, proliferation
rate, cell migration, cell viability, gene expression, protein
expression, protein levels in the culturing medium,
dedifferentiation, growth characteristics, and/or cell
morphology.
[0130] Agents are screened for biological activity by adding the
agent to at least one and usually a plurality of cell samples. The
change in parameters in response to the agent is measured, and the
result evaluated by comparison to reference cultures, e.g. in the
presence and absence of the agent, obtained with other agents, etc.
The agents may be conveniently added in solution, or readily
soluble form, to the medium of cells in culture. The agents may be
added in a flow-through system, as a stream, intermittent or
continuous, or alternatively, by adding a bolus of the compound,
singly or incrementally, to an otherwise static solution. In a
flow-through system, two fluids are used, where one is a
physiologically neutral solution, and the other is the same
solution with the test compound added. The first fluid is passed
over the cells, followed by the second. In a single solution
method, a bolus of the test compound is added to the volume of
medium surrounding the cells. The overall concentrations of the
components of the culture medium should not change significantly
with the addition of the bolus, or between the two solutions in a
flow through method.
[0131] Various methods can be utilized for quantifying the presence
of the selected markers. For measuring the amount of a molecule
that is present, a convenient method is to label a molecule with a
detectable moiety, which may be fluorescent, luminescent,
radioactive, enzymatically active, etc., particularly a molecule
specific for binding to the parameter with high affinity
fluorescent moieties are readily available for labeling virtually
any biomolecule, structure, or cell type. Immunofluorescent
moieties can be directed to bind not only to specific proteins but
also specific conformations, cleavage products, or site
modifications like phosphorylation. Individual peptides and
proteins can be engineered to autofluoresce, e.g. by expressing
them as green fluorescent protein chimeras inside cells. Thus,
antibodies can be modified to provide a fluorescent dye as part of
their structure. Depending upon the label chosen, parameters may be
measured using other than fluorescent labels, using such
immunoassay techniques as radioimmunoassay (RIA) or enzyme linked
immunosorbance assay (ELISA), homogeneous enzyme immunoassays, and
related non-enzymatic techniques. The quantization of nucleic
acids, especially messenger RNAs, is also of interest as a
parameter. These can be measured by hybridization techniques that
depend on the sequence of nucleic acid nucleotides. Techniques
include polymerase chain reaction methods as well as gene array
techniques.
[0132] Encapsulation
[0133] Any encapsulation protocol known in the art may be used with
the OPCs of the present invention. The OPCs of the present
invention may be encapsulated and used to deliver biologically
active molecules, according to known encapsulation technologies,
including microencapsulation (see, e.g., U.S. Pat. Nos. 4,352,883;
4,353,888; and 5,084,350, incorporated herein by reference),
macroencapsulation (see, e.g., U.S. Pat. Nos. 5,284,761, 5,158,881,
4,976,859 and 4,968,733 and published PCT patent applications WO
92/19195, WO 95/05452, each incorporated herein by reference).
[0134] If the OPCs are encapsulated, macroencapsulation as
described in U.S. Pat. Nos. 5,284,761; 5,158,881; 4,976,859;
4,968,733; 5,800,828 and published PCT patent application WO
95/05452, each incorporated herein by reference is preferred. Cell
number in the devices can be varied. Preferably each device
contains between 10.sup.3-10.sup.9 cells, most preferably
10.sup.5-10.sup.7 cells. A large number of macroencapsulation
devices may be implanted in the patient; preferably between one to
10 devices.
[0135] The following examples are illustrative, but not limiting,
of the methods and compositions of the present invention. Other
suitable modifications and adaptations of the variety of conditions
and parameters normally encountered in therapy and that are obvious
to those skilled in the art are within the spirit and scope of the
embodiments.
Example 1
Selection of PDGFR Positive Cells
[0136] Fetal brain (16-20 weeks of gestation) was enzymatically
treated with a combination of collagenase/hyaluronidase and trypsin
to generate a single cell suspension. Cells were ressuspended in
Hank's balanced salt solution containing 1 mM Sodium Pyruvate and
0.1% human serum albumin (staining buffer) and stained with the
CD133 antibody. CD133.sup.+ cells were aseptically sorted using a
BD Vantage flow cytometer, under enrichment mode. CD133.sup.+
enriched fraction was centrifuged, ressuspended in staining buffer
and incubated with a 1:100 dilution of rabbit anti PDGFR.alpha.
polyclonal antibody (IgG) for 2 hours at 4.degree. C. After two
rinses in staining buffer, PDGFR.alpha. labeled cells were
incubated for polyclonal goat anti-rabbit IgG-FITC antibody
(Caltag). PDGFR.alpha. positive (FITC labeled) cells were
aseptically sorted using a BD Vantage flow cytometer, under purity
mode. Sorted cells were cultured on poly-L-ornithine, laminin and
fibronectin coated culture flasks in DMEM medium supplemented with
B27, N2, NAC, L-Glutamine, Na Pyruvate, FGF2, PDGF-AA and NT3
(complete medium), with or without IGF1. Cell passaging was
achieved by mild trypsin treatment and re-plating in the same
medium.
[0137] An alternative method used for the purification of
PDGFR.alpha. positive cells is to stain total brain cells (with or
without enrichment for CD133) with the mouse monoclonal antibody
1:50 PDGFR.alpha.-PE (Pharmingen) for 2 h at 4.degree. C., followed
by purity aseptic sorting using a BD Aria flow cytometer.
Example 2
Selection of CD105 Negative Cells
[0138] The use of CD105.sup.- cells as a selection marker is based
on the present inventors discovery that some cultures of purified
PDGFR.alpha..sup.+ cells expand at a much faster rate then others.
Such accelerated growth was generally accompanied by the appearance
of a cell type with a morphology distinct from that of
oligodendrocyte progenitors. Based on the morphology and
accelerated growth in culture, it is likely that these cells are
PDGFR.alpha..sup.+ fibroblasts; the growth advantage of fibroblasts
in FGF2 containing media is well documented. Moreover, apart from
exhausting mitogens, fibroblasts may also negatively condition the
culture medium, affecting the growth kinetics and the
differentiation process of oligodendrocyte progenitors into
oligodendrocytes, both in vitro and in vivo. The presence of these
fibroblastic cells therefore reduces the efficiency in obtaining an
expanded culture of oligodendrocyte progenitors.
[0139] It is desirable to define a more pure and homogeneous
oligodendrocyte progenitor population, especially in the case when
contaminating cells have growth advantage. Therefore a search was
initiated for cell surface markers expressed specifically in
fibroblasts that could be used to distinguish them from
PDGFR.alpha..sup.+ oligodendrocyte progenitors. A panel of
antibodies was used to stain cultures containing a mixture of
fibroblasts and oligodendrocytes. The results showed that the
monoclonal antibody to CD105, which recognizes the glycoprotein
endoglin, is a useful reagent to subdivide the PDGFR.alpha..sup.+
population into two subpopulations: PDGFR.alpha..sup.+ CD105.sup.+
(fibroblasts) and PDGFR.alpha..sup.+ CD105.sup.- (oligodendrocyte
progenitors).
[0140] The sorting protocol for the isolation of fetal derived
human oligodendrocyte progenitors includes two antibodies,
CD105-APC and PDGFR.alpha.-PE. Various cell lots have been
generated using this two antibody protocol. The results indicate
that these cell lots have similar growth characteristics and
oligodendrocyte differentiation potential. Further, the appearance
of fibroblasts is not observed in these cultures, up to passage 15,
the highest passage tested. The results demonstrate that CD105 is a
useful negative selection marker for use in obtaining a desirable
population of oligodendrocyte progenitors.
Example 3
Media for Proliferating OPCs
[0141] Proliferation medium was prepared with the following
components in the indicated concentrations: Component Final
Concentration DMEM, glutamine (Invitrogen, cat#25030-081) 2 mM, Na
Pyruvate (Sigma, cat#S8636), 1 mM, NAC (Sigma, cat#A9165), 1 mM, N2
supplement (Invitrogen, cat#17502-048; containing transferrin,
insulin, putrescine, selenium and progesterone), B27 supplement
(Invitrogen, cat #17504-044), 20 ng/ml human bFGF (Biosource,
cat#PHG0024), 20 ng/ml PDGF-AA (Peprotech, cat#100-13A) 10 ng/ml
NT3 (Peprotech, cat#450-03), 100 ng/ml IGF1 (Peprotech, cat
#AF-100-11).
Example 4
Differentiation of OPCs
[0142] In a first differentiation protocol, proliferating OPCs are
induced to differentiate by physical removal or exhaustion of the
growth factor mitogens from the cell culture with addition of
triiodothyronine (T3).
[0143] The staining protocol for oligodendrocytes was as
follows:
[0144] O4 Staining for Oligodendrocytes. Cells are incubated with
primary antibodies to O4 (hybridoma supernatant, mouse monoclonal;
used at 1:2) for 30 min at room temperature. Cells are washed once
with 0.1 M PBS, pH 7.4. Cells are fixed for 20 min at room
temperature with ice-cold 4% paraformaldehyde. Cells are washed
twice for 5 min with 0.1 M PBS, pH 7.4. Cells preparations are
blocked for 30 min at room temperature in 10% horse serum ("HS")
diluted in 0.1M PBS, pH 7.4. Cells are incubated with secondary
antibodies (donkey anti mouse IgG/Alexa488 used at 1:500,
(Invitrogen, Cat#A21202); or goat anti mouse IgM/Alexa 488,
(Invitrogen, Cat#A21042) diluted in 1% HS for 1 hr at room
temperature in the dark. Preparations are washed twice for 5 min
with 0.1 M PBS in the dark. Preparations are mounted onto slides
face down with mounting medium (Vectashield Mounting Medium, Vector
Laboratories, cat#H-1000) or left on culture wells for
quantification and qualification of staining and stored at
4.degree. C.
[0145] In some instances stain with Hoechst (a nuclear stain) may
be used as follows. Cells prepared as above are washed with Hoechst
solution (diluted 1:10,000 in 0.1% saponin, Sigma, Cat#54521).
Cells are incubated in Hoechst solution for 5 min at room
temperature, followed by 2 washes in 0.1M PBS.
Example 5
Differentiation of OPCs
[0146] In a second differentiation protocol, the OPCs are induced
to differentiate by removal of the growth factor mitogens and
provision of 1% serum. This differentiation protocol produces cell
cultures highly enriched in oligodendrocytes.
[0147] In a third differentiation protocol, the OPCs are induced to
differentiate by removal of the growth factor mitogens and
provision of 30 nM T3 (Sigma, cat#T5516). This differentiation
protocol produces cell cultures highly enriched in
oligodendrocytes.
Example 6
Encapsulation
[0148] If the OPCs are encapsulated, then the following procedure
may be used: The hollow fibers are fabricated from a polyether
sulfone (PES) with an outside diameter of 720 m and a wall
thickness of a 100 m (AKZO-Nobel Wuppertal, Germany). These fibers
are described in U.S. Pat. Nos. 4,976,859 and 4,968,733, herein
incorporated by reference. The fiber may be chosen for its
molecular weight cutoff. A PES#5 membrane which has a MWCO of about
280 kd is occasionally used. In other studies, a PES#8 membrane
which has a MWCO of about 90 kd may be used.
[0149] The devices typically comprise: 1) a semipermeable
poly(ether sulfone) hollow fiber membrane fabricated by AKZO Nobel
Faser AG; 2) a hub membrane segment; 3) a light cured methacrylate
(LCM) resin leading end; and 4) a silicone tether.
[0150] The semipermeable membrane used typically has the following
characteristics: Internal Diameter 500+30 m Wall Thickness 100+15 m
Force at Break 100+15 cN Elongation at Break 44+10% Hydraulic
Permeability 63+8 (ml/min m.sup.2 mmHg) nMWCO (dextrans) 280+20
kd.
[0151] The components of the device are commercially available. The
LCM glue is available from Ablestik Laboratories (Newark, Del.);
Luxtrak Adhesives LCM23 and LCM24). The tether material is
available from Specialty Silicone Fabricators (Robles, Calif.). The
tether dimensions are 0.79 mm ODX0.43 mm IDXlength 202 mm. The
morphology of the device is as follows: The inner surface has a
permselective skin. The wall has an open cell foam structure. The
outer surface has an open structure, with pores up to 1.5 m
occupying 30+5% of the outer surface.
[0152] Fiber material is first cut into 5 cm long segments and the
distal extremity of each segment sealed with a photopolymerized
acrylic glue (LCM-25, ICI). Following sterilization with ethylene
oxide and outgassing, the fiber segments are loaded with a
suspension of between 10.sup.4-10.sup.7 cells, either in a liquid
medium, or a hydrogel matrix (e.g., a collagen solution
(Zyderm.TM.), alginate, agarose or chitosan) via a Hamilton syringe
and a 25 gauge needle through an attached injection port. The
proximal end of the capsule is sealed with the same acrylic
glue.
[0153] A silicone tether (Specialty Silicone Fabrication, Taunton,
Ma.) (ID: 690 m; OD: 1.25 mm) is placed over the proximal end of
the fiber allowing easy manipulation and retrieval of the
device.
Example 7
Transplantation of OPCs
[0154] Target OPCs may be transplanted into rodent brain to assess
graft viability, integration, phenotypic fate of the grafted cells,
as well as behavioral changes associated with grafted cells in
healthy animals.
[0155] Transplantation is performed according to standard
techniques. For example, adult rats are anesthetized with sodium
pentobarbitol (45 mg/kg, i.p.) and positioned in a Kopf stereotaxic
instrument. A midline incision is made in the scalp and a hole
drilled for the injection of cells. Rats receive implants of target
OPCs into the striatum using a glass capillary attached to a 10
.mu.l Hamilton syringe. Each animal receives a total of about
250,000-500,000 cells in a total volume of 2 .mu.l. Cells are
transplanted 1-2 days after passaging and the cell suspension is
made up of undifferentiated OPC clusters of 5-20 cells. Following
implantation, the skin is sutured closed.
Example 8
Transplantation of OPCs into Rodent Models of Dysmyelinating
Disease
[0156] Target OPCs may be transplanted into rodent brain to assess
graft viability, integration, phenotypic fate of the grafted cells,
as well as behavioral changes associated with grafted cells in
lesioned or diseased animals.
[0157] Transplantation is performed according to standard
techniques. For example, newborn and rats or jimpy mice are
anesthetized by hypothermia and positioned in a Kopf stereotaxic
instrument. A midline incision is made in the scalp and a hole
drilled for the injection of cells. Animals receive implants of
target OPCs into the corpus callosum, fimbria, cerebellar peduncle
and/or spinal cord using a glass capillary attached to a 10 .mu.l
Hamilton syringe. Each animal receives a total of about
300,000-600,000 cells in a total volume of 6 .mu.l. Cells are
transplanted immediately or 1-2 days after passaging and the cell
suspension is made up of undifferentiated single OPCs or clusters
of 5-20 cells. Following implantation, the skin is sutured or
staple closed.
[0158] Alternatively, newborn or juvenile shiverer mice are
anesthetized by hypothermia or isofluorane and positioned in a Kopf
stereotaxic instrument. A midline incision is made in the scalp and
a hole drilled for the injection of cells. Mice receive implants of
target OPCs into the corpus callosum, fimbria, cerebellar peduncle
and/or spinal cord using a glass capillary attached to a 10 .mu.l
Hamilton syringe. Each animal receives a total of about
300,000-600,000 cells in a total volume of 6 .mu.l. Cells are
transplanted immediately or 1-2 days after passaging and the cell
suspension is made up of undifferentiated single OPCs or clusters
of 5-20 cells. Following implantation, the skin is sutured or
staple closed.
Example 9
Treatment of Neurodegenerative Disease Using Progeny of Target OPCs
In Vitro
[0159] Target OPCs are obtained from fetal brain tissue following
routine suction abortion which is collected into a sterile
collection apparatus. A 2.times.4.times.1 mm piece of tissue is
dissected and dissociated as in Examples 1 or 2. Target OPCs are
then proliferated. The target OPC progeny are used for
neurotransplantation into a blood-group matched host with a
neurodegenerative disease. Surgery is performed using a BRW
computed tomographic (CT) stereotaxic guide. The patient is given
local anesthesia suppiemencea with intravenously administered
midazolam. The patient undergoes CT scanning to establish the
coordinates of the region to receive the transplant. The injection
cannula consists of a 17-gauge stainless steel outer cannula with a
19-gauge inner stylet. This is inserted into the brain to the
correct coordinates, then removed and replaced with a 19-gauge
infusion cannula that has been preloaded with 30 .mu.l of tissue
suspension. The cells are slowly infused at a rate of about 3
.mu.l/min as the cannula is withdrawn. Multiple stereotactic needle
passes are made throughout the area of interest, approximately 4 mm
apart. The patient is examined by CT scan postoperatively for
hemorrhage or edema. Neurological evaluations are performed at
various post-operative intervals, as well as PET scans to determine
metabolic activity of the implanted cells.
Example 10
Genetic Modification of Target OPC Progeny Using Calcium Phosphate
Transfection
[0160] Target OPC progeny are propagated as described herein. The
cells are then transfected using a calcium phosphate transfection
technique. For standard calcium phosphate transfection, the cells
are mechanically dissociated into a single cell suspension and
plated on tissue culture-treated dishes at 50% confluence
(50,000-75,000 cells/cm.sup.2) and allowed to attach overnight.
[0161] The modified calcium phosphate transfection procedure is
performed as follows: DNA (15-25 .mu.g) in sterile TE buffer (10 mM
Tris, 0.25 mM EDTA, pH 7.5) diluted to 440 .mu.l with TE, and 60
.mu.l of 2M CaCl.sub.2 (pH to 5.8 with 1M HEPES buffer) is added to
the DNA/TE buffer. A total of 500 .mu.l of 2.times. HeBS
(HEPES-Buffered saline; 275 mM NaCl, 10 mM KCl, 1.4 mM Na.sub.2
HPO.sub.4, 12 mM dextrose, 40 mM HEPES buffer powder, pH 6.92) is
added dropwise to this mix. The mixture is allowed to stand at room
temperature for 20 minutes. The cells are washed briefly with
1.times. HeBS and 1 ml of the calcium phosphate precipitated DNA
solution is added to each plate, and the cells are incubated at
37.degree. for 20 minutes. Following this incubation, 10 mls of
complete medium is added to the cells, and the plates are placed in
an incubator (37.degree. C., 9.5% CO.sub.2) for an additional 3-6
hours. The DNA and the medium are removed by aspiration at the end
of the incubation period, and the cells are washed 3 times with
complete growth medium and then returned to the incubator.
Example 11
Genetic Modification of Target OPCs Using Viral Vectors
[0162] Target OPCs are proliferated as described herein and then
infected with lentiviral vectors containing genes of interest in
addition to a report gene such as GFP (green fluorescence protein).
Lentivirus suspensions are added to the culture medium where OPCs
are proliferated and incubated for 24 hours. After 24 h, the
culture medium is removed and replaced with fresh medium and the
OPCs are cultured for another 3 days. Cells are collected and
centrifuged and cells expressing the gene of interest are sorted by
flow cytometry. Positive cells are returned to the proliferative
medium.
[0163] The transduced OPC progeny are transplanted into a rodent or
human patient using the procedures described in the previous
Examples.
Example 12
Transplantation of OPCs into Rodent Models of Spinal Cord
Injury
[0164] Target OPCs may be transplanted into rodent spinal cord to
assess graft viability, integration, phenotypic fate of the grafted
cells, as well as behavioral changes associated with grafted cells
in spinal cord lesioned animals.
[0165] Animals receive a laminectomy at vertebral level T9. Animals
then receive a 50-kilodyne (kd) contusion spinal cord injury using
an Infinite Horizon Impactor (Precision Systems and
Instrumentation, Lexington, Ky.). Seven days after spinal cord
injury, mice are tested using the Basso, Beattie, and Bresnahan
(BBB) rating scale and randomized to receive OPCs or vehicle
control. Cells are injected bilaterally anterior and posterior to
the epicenter of the lesion using a beveled grass micropipette
affixed to a nanoinjector device. Each animal receives 50,000 to
80,000 cells.
Example 13
Transplantation of OPCs into Rodent Models of MS
[0166] Myelin oligodendrocyte glycoprotein (MOG)-induced murine
experimental autoimmune encephalomyelitis (EAE) is a widely
accepted model for studying the clinical and pathological features
of multiple sclerosis.
[0167] Transplantation is performed according to standard
techniques. For example, adult animals affected by MOG-induced EAE
are anesthetized using isoflurane gas and positioned in a Kopf
stereotaxic instrument. A midline incision is made in the scalp and
a hole drilled for the injection of cells. Animals receive implants
of target OPCs into the corpus callosum, fimbria, cerebellar
peduncle, lateral ventricular space and/or spinal cord using a
glass capillary attached to a 10 .mu.l Hamilton syringe. Each
animal receives a total of about 300,000-600,000 cells in a total
volume of 6 .mu.l. Cells are transplanted immediately or 1-2 days
after passaging and the cell suspension is made up of
undifferentiated single OPCs or clusters of 5-20 cells. Following
implantation, the skin is sutured or staple closed.
Example 14
Characterization of the Engraftment Ability of Expanded
PDGFR.sup.+CD105.sup.- Oligodendrocyte Progenitor (OPC)
Population
[0168] In order to determine whether FACS-isolated, in vitro
expanded oligodendrocyte progenitor cells survive, migrate and are
capable of in vivo myelination, a series of transplantation studies
were conducted using the shiverer mouse, a rodent model of
dysmyelination. The shiverer mouse contains a naturally occurring
deletion of a large portion of the mbp gene which results in
incomplete CNS myelin formation. In order to avoid xenogenic
rejection of human cells, the shiverer mice were backcrossed to the
immunodeficient NOD-Scid mouse. Engraftment of oligodendrocyte
progenitors was studied in two different Shiverer/Scid age groups:
as juveniles (P21-P30) and as neonates (P0-P1). Shiverer/Scid mice
have a relatively short lifespan of around 8 weeks and therefore
the longest post transplantation time point studied was about 8
weeks in the case of neonatal injections and 5 weeks for juvenile
injections.
[0169] Oligodendrocyte progenitors are grown as a monolayer. In
order to prepare cells for transplantation, OPCs were lifted off
the flasks using trypsin, following a protocol similar to that used
to passage OPCs. Cells were then exposed to trypsin inhibitor to
stop the proteolytic digestion, washed twice in culture medium and
ressuspended in ex-vivo medium containing the antioxidant NAC (1
mM) at a final density of 1E5 cells/.mu.l.
[0170] The ability for OPCs to be held in a suspension culture
format for at least one day post trypsin treatment was tested. This
1-day hold period in suspension could be advantageous for 3
reasons: 1) would allow cells to recover from a potentially
damaging enzyme treatment prior to transplantation and/or
cryopreservation; 2) it would introduce more flexibility in animal
surgery scheduling and 3) would make shipment of
ready-to-transplant OPCs to an off-site location (laboratory or
clinic) possible. Finally, and given the potential application of
OPCs for clinical application, the engraftment ability and
myelination potential of OPCs after cryopreservation was tested
with positive results.
Example 15
Transplantation
[0171] Juvenile or neonatal shiverer/Scid mice were placed in a
stereotaxic frame and 1 .mu.l of OPC suspension was injected into
2-3 brain locations, bilaterally (4-6 total injections/mouse).
Injections targeted the corpus callosum, fimbria and the cerebellar
peduncle (see FIG. 1), regions of the brain that are heavily
myelinated (rich in white matter) in myelin-competent animals but
severely hypomyelinated in the shiverer/scid mouse. Mice were
sacrificed at different time points, up to 8 weeks, and their
brains analyzed for the presence of human cells using the
monoclonal antibody SC121 and for the presence of human derived
oligodendrocytes, capable of myelinating mouse axons, using an MBP
antibody. Because shiverer mice have a mutation that deletes most
of the mbp gene, MBP protein is not produced by mouse
oligodendrocytes and therefore any MBP detected by the anti-MBP
antibody is of human origin.
TABLE-US-00001 TABLE 15-1 Summary of engraftment data obtained from
4 OPC lines derived from 4 different donor tissues. Total #
Presence Myelin Shiverer age transplanted of donor production Donor
ID, age Passage tested group Shi/Scid mice cells SC121.sup.+
MBP.sup.+ 2657, 18 wks 3, 13 & 14 Juvenile 10 10/10 10/10 2703,
18 wks 6, 9, 14, 15 & 16 Juvenile & 4 juv + 15 neo 19/19
19/19 Neonates 2710, 18 wks 2 Neonates 2 2/2 2/2 2711, 18 wks 4, 6,
11 & 12 Neonates 16 16/16 16/16
[0172] All juvenile and neonatal animals injected with OPCs
contained human cells (as determined by SC 121 staining) at all
ages tested. When stained for MBP, all animals also demonstrated
positive staining (see FIG. 2 for one example of SC121 and MBP
staining in serial sections).
[0173] The possibility of genetically modifying OPCs with
lentiviral vectors was also tested. As a proof of concept, we used
a lentiviral vector expressing the reporter gene GFP (green
fluorescence protein) under the control of the MBP promoter. This
allows for direct visualization (antibody staining free) of the
OPCs that are actively transcribing the MBP gene (bright green
cells) and that have the morphology of mature myelinating
oligodendrocytes (multiple processes with cable like morphology,
aligned with axonal bundles). FIG. 3 shows one example of a
shiverer/scid mouse transplanted with MBP-GFP OPCs, sacrificed at 8
weeks post transplantation.
[0174] The in vivo study showed that neonates and juvenile shiverer
mice are appropriate models for testing engraftment and myelination
ability of expanded OPCs. Major differences in the engraftment
quality between neonate and juvenile shiverer/scid mice were not
observed.
[0175] The in vivo study showed that engraftment of OPCs and
myelination were not significantly affected by passage number; for
instance, in neonates that were injected with donor 2703, there was
no qualitative difference in the total number of human cells and
the extent of myelination, suggesting that potency (ability to
engraft and to myelinate) does not diminish with passage up to
passage 16, the longest passage number tested.
[0176] The in vivo study showed that when the potency of freshly
passaged (never frozen) OPCs is compared with that of previously
cryopreserved OPCs at the same or similar passage, there were no
major qualitative differences in engraftment and myelination.
Although only neonatal animals were transplanted with previously
cryopreserved cells, we do not expect a different outcome in
juvenile animals. This result indicates that OPC cultures can be
cryoprotected without any detectable loss in potency. Similarly,
there is no loss of potency (engraftment or myelination ability)
due to the one-day hold period, suggesting that this protocol can
be used to facilitate OPC culture transfers to off site locations
in a ready-to-use format.
EQUIVALENTS
[0177] The details of one or more embodiments of the invention are
set forth in the accompanying description above. Although any
methods and materials similar or equivalent to those described
herein can be used in the practice or testing of the present
invention, the preferred methods and materials are now described.
Other features, objects, and advantages of the invention will be
apparent from the description and from the claims. In the
specification and the appended claims, the singular forms include
plural referents unless the context clearly dictates otherwise.
Unless defined otherwise, all technical and scientific terms used
herein have the same meaning as commonly understood by one of
ordinary skill in the art to which this
* * * * *